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Abstracts of proffered papers
Gynaecological Cancer
Radical hysterectomy is overtreatment for early stage cervix
cancer
E.J. Buxton', N. Saunders2, M.E.L. Patterson2, C. Hilton',
D.M. Luesley3, C.W.E. Redman1, J.J. Mould' &
G. Blackledgel
1 West Midlands Cancer Research Campaign Clinical Trials
Unit; 2Northern General Hospital, Sheffield and 3Dudley
Road Hospital, Birmingham, UK.
Radical hysterectomy with pelvic lymphadenectomy has been
regarded as the optimal surgical approach in managing early
invasive cervix cancer. Pelvic lymphadenectomy has not been
shown to improve prognosis in node positive patients and is
probably unnecessary in patients with negative nodes. Wide
parametrial excision has considerable morbidity. We report a
retrospective analysis of surgically managed early stage
disease the aims of which were: to define the incidence of
parametrial tumour extension and to assess the therapeutic
benefit of wide parametrial excision.
The case records and pathology reports of 141 patients
who underwent radical hysterectomy with pelvic lymph-
adenectomy between 1980 and 1987 were reviewed (median
follow-up 32 months). Nine (6.3%) had direct tumour
extension into the parametrium (5 with positive and 4 with
negative nodes). Four of five node positive patients received
post operative external beam radiotherapy (EBRT) and three
have relapsed (2 with pelvic and distant and 1 with only
distant recurrence). In the four node negative patients 2
received post operative EBRT and one has relapsed with
pelvic disease. Twenty of the remaining 132 patients were
node positive and 112 were node negative. Thirteen with
positive nodes received EBRT and three have relapsed (1
with pelvic and 2 with pelvic and distant recurrence). Three
of the remaining seven node positive patients have relapsed
(2 with pelvic and 1 with pelvic and distant recurrence).
Fifteen node negative patients have relapsed (9 with pelvic, 3
with pelvic and distant and 3 with distant recurrence alone).
There was no signifiant difference in relapse rate between
patients with positive nodes who did or did not receive post
operative EBRT.
The only patients who can be regarded as benefiting from
wide parametrial excision are those with direct tumour
extension to the parametrium who have negative nodes and
do not subsequently relapse, i.e. three of 141 patients (2.1%).
These data do not support the hypothesis that wide para-
metrial excision is of therapeutic benefit and question the
value of post operative pelvic radiotherapy. There may be
potential for management of small volume early stage dis-
ease by simple hysterectomy followed by adjuvant therapy
where tumour spread to the parametrium or pelvic nodes is
found to have occurred.
*Enquiries to the BOA Secretariat, The British Postgraduate
Medical Federation, 33 Millman Street, London WC1N 3EJ, UK.
tReprints of these abstracts are not available - Ed.
Survival of younger cervical carcinoma patients treated by
radical radiotherapy in the West of Scotland 1964-1984
E.J. Junior, R.P. Symonds, E.R. Watson & D.W. Lamont
Beatson Oncology Centre, Glasgow, UK.
Overall mortality from carcinoma of cervix has declined
since the mid 1950s, but the death rate from this disease
amongst younger women has risen.
Between 1964 and 1984, 2,011 patients in the West of
Scotland were treated by radical radiotherapy for carcinoma
of the cervix. The percentage of patients aged <35 years has
risen from 4% to 10% in the twenty years, but younger
patients have presented with earlier stage disease, unlike the
pattern of stage distribution seen in patients aged >45 years.
All patients allocated the same FIGO stage were treated
by identical radiotherapeutic technique and dose, irrespective
of age or histology. Survival data from at least five year
follow up was analysed, relative to stage, age and histo-
logical grade.
There was no statistically significant difference in survival
for any age group within the same stage category, nor was
there any correlation with histological grade, despite an
increase in the number of poorly differentiated tumours,
especially in women aged <45 years. Overall, younger
patients in the West of Scotland have a better prognosis than
patients aged over 45 years, mainly due to early
presentation.
This analysis suggests that the rise in mortality of younger
patients from carcinoma of cervix is due to an increased
incidence of the disease in younger women, rather than to a
more virulent form of the disease.
Randomised trial of JM8 (carboplatinum) versus JM9
(CHIP) in untreated carcinoma of the ovary
C.W.L. Trask, A.C. Silverstone, R.L. Souhami, H.M. Earl,
C.M. Ash, C. Irwin & J.S. Tobias
Southend Hospital and University College Hospital, London,
UK.
Between August 1984 and October 1987, 120 patients with
Stage IC-IV epithelial ovarian cancer were randomly
assigned to receive JM8 (400mgm-2 or JM9 (300mgm-2)
every 4 weeks as primary therapy. Stratification was made
according to FIGO stage and to size of residual disease
after surgery.
Following six courses patients were re-staged and response
evaluated. Investigations include laparoscopy in clinical com-
plete responders or those with no evaluable disease. Treat-
ment was then stopped in pathological complete responders.
Partial responders continued with a further six courses of
their original drug at a reduced dose (JM8 300mgm 2, JM9
225mgm-2). Patients with stable, progressive or recurrent
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disease were treated with cyclophosphamide (1 gm-2). There
was no cross over between the two arms of the study.
The response rates were 62% for JM8 and 36% for JM9.
Sixteen patients were unevaluable for response. The median
survival is 96 weeks for JM8 patients and 68 weeks for JM9
patients (P=0.1319). The amount of residual disease after
initial laparotomy was a prognostic factor for survival.
Myelosuppression was the main toxicity and was greater
with JM9.
The study shows JM8 to be more active than JM9 in the
treatment of ovarian cancer and less toxic. Few responses to
cyclophosphamide occurred following either drug, implying
resistance to the alkylating agent.
Intraperitoneal radioimmunotherapy for ovarian cancer.
Radiopharmacokinetics, toxicity and efficacy of 1311 labelled
monoclonal antibodies
J.S.W. Stewart, V. Hird, H.E. Lambert & A.A. Epenetos
Imperial Cancer Research Fund and Department of Clinical
Oncology, Hammersmith Hospital, London, UK.
Thirty-six patients with ovarian cancer were treated with
intraperitoneal 131I labelled monoclonal antibodies. The
activity of 1311 administered was increased from 20mCi to
158mCi and toxicity and efficacy evaluated. Detailed
pharmacokinetic studies were undertaken in 11 patients and
compared to those of five retreated patients who had
developed antibodies against the mouse immunoglobulin.
Patients receiving their first treatment had a maximum of
25% (range 19.8-39.8%) of the injected activity in their
circulation. This was accompanied by marrow suppression at
1311 activities over 120mCi. The five retreated patients had
only 5% of the injected activity in their circulation (range
3.8-6%), with rapid urinary excretion and negligible marrow
suppression.
In the 31 patients with assessable disease there was no
response in eight patients with gross disease (nodules
>2cm), a partial response in 2 out of 15 patients with
nodules <2cm, and complete response in three out of 6
patients with microscopic residual disease. The non-specific
radiation dose to the peritoneal serosa was measured by
lithium fluoride thermoluminescent radiation dosimetry in 11
patients. The dose received by the peritoneal serosa was less
than 500cGy.
It is concluded that i.p. 1311 labelled antibodies may be
effective against very small tumour deposits. The local
radiation dose to the normal peritoneal serosa is low due to
the efficient systemic absorption of antibody. Bone marrow
suppression is the dose limiting factor. This may be reduced
by administering concurrent systemic anti-mouse
immunoglobulin.
D-TRP-6-LHRH (decapeptyl): A new treatment in advanced
ovarian cancer
H. Parmar, R.H. Phillips, G. Rustin & S.L. Lightman
Charing Cross and Westminster Medical School,
Westminster Hospital, London, UK.
Ovarian cancer cells have been shown to have oestrogen and
progesterone receptors and antioestrogen and progesterone
have been used in therapy of ovarian cancer. Recently LH
(hCG) receptors have been identified in ovarian cancer
tissues and in vitro studies have demonstrated growth of
human ovarian cancer cell lines treated with commercial LH
(hCG) preparations from the urine of pregnant females. We
treated 39 patients with advanced ovarian cancer (FIGO
stage III or IV) who had relapsed following conventional
treatment. The D-Trp-6-LHRH microcapsules were adminis-
tered once a month. There were no exclusion criteria and
patients of any age or performance status were eligible. Six
patients achieved a partial remission where the tumour
decreased in volume more than 50%. The responses were
maintained for a mean duration of 10 months (range 6-18
months). Twenty-eight patients continued to have progress-
ive disease and 25 died within the first 16 weeks from the
start of therapy reflecting the poor performance status of
these patients. Five patients remained stable on D-Trp-6-
LHRH for varying periods from 3-12 months. The respond-
ing patients had a significantly longer survival than non-
responding patients. Therefore, 11 patients (6PR+5SD) have
had remission or stabilization of disease which has been
clinically worthwhile. This clinical benefit with slow-release
D-Trp-6-LHRH in -27% of patients is highly encouraging
and offers an important non-toxic alternative in patients who
are either intolerant of chemotherapy or in those patients
who have progressive disease following chemotherapy.
Head and Neck Cancer
Production of transforming growth factors alpha and beta by
oral squamous cell carcinoma, human skin and cultured
keratinocytes
M. Partridge
Charing Cross Sunley Research Centre, London and
Unilever Research, Sharnbrook, Bedford, UK.
There is evidence for normal and abnormal growth control
mechanisms involving growth promoting and inhibiting
factors. We have examined a series of oral squamous cell
carcinomas (SCC), skin and cultured keratinocytes for the
production of transforming growth factor alpha (TGFax),
transforming growth factor beta (TGF#) and in some cases
for the presence of epidermal growth factor receptor
(EGFR). The experiments were designed to investigate
whether these factors are produced locally in tissues and
hence potentially play a role in normal and malignant cell
growth.
Using northern blotting and radioimmunoassay we
detected TGFa and # in normal skin and cultured keratino-
cytes. Addition of EGF to cultured keratinocytes resulted in
increased secretion of TGFoa and # suggesting that produc-
tion of these factors may be regulated by exogenous growth
factors.
We find a relationship between the presence of TGFa and
its receptor (EGFR) in oral SCC which also suggests an
autocrine loop influencing growth of these tumours. An
inverse correlation between the level of TGFa detected and
EGFR expression was observed. This may be explained by
proposing active metabolism and degradation of TGFa via
the EGFR in SCC. TGFfl was also detected in these
tumours but evidence suggests that the tumour may be
unable to respond to the inhibitory effects of this ligand
(Ozanne et al., J. Pathol., 149, 9, 1986). This lack of normal
inhibitory regulatory control may be related to continued
tumour growth.
Human cell kinetic data and the programming of
radiotherapy
M.I. Saunders, S. Dische, M.H. Bennett, G. Wilson &
N. McNally
Mount Vernon Hospital, Northwood, UK.
The administration of bromodeoxyuridine with delayed
tumour sampling has given cell kinetic data in 75 human520 THIRD MEETING OF THE BRITISH ONCOLOGICAL ASSOCIATION
tumours. Conventional views on the rate of growth of
human tumours, based on histopathology, must be revised in
a number of tumours in the light of this new knowledge.
Verrucal carcinoma is generally regarded as a slowly
growing tumour and one difficult to cure by radiotherapy.
Four cases will be described where cell kinetic studies have
been performed. In all four, cell cycle times were remarkably
short indicating that there was a potential for rapid cellular
proliferation. This can be contrasted with the apparently
slow rate of increase in size associated with such a tumour.
Three of these patients were treated by a regime of con-
tinuous, hyperfractionated, accelerated radiotherapy in which
36 fractions were given over a period of 12 days (CHART).
All have shown a complete regression of tumour. The final
case was treated by surgery.
A wide range of head and neck tumours have been treated
with the CHART regime and results showed significant
improvement when comparison was made with previously
treated cases. Cell kinetic studies performed in many of these
tumours showed that in most there was a capacity for rapid
repopulation. Such a capacity is likely to be expressed once
cell destruction occurs on initiation of treatment. Cell kinetic
data are likely to be a major influence in the programming
of cancer treatment.
A controlled prospective randomised trial of combination
chemotherapy administered synchronously or sequentially
with radical radiotherapy: An analysis of prognostic factors
in advanced squamous carcinoma of the head and neck
F.M.B. Calman
On behalf of the SECOG Trial Steering Committee, UK.
Between February 1980 and June 1986, 361 patients with
advanced (Stages III and IV) squamous cancer of the head
and neck were randomised into a trial comparing combi-
nation chemotherapy (vincristine, bleomycin and methotrex-
ate) given either synchronously or sequentially with radical
radiotherapy. A further randomisation was made between
the addition of 5-fluoro-uracil and no 5-fluoro-uracil in a 2-
by-2 factorial design. There was no significant difference
between the two arms of the trial although patients receiving
5-FU had improved disease-free survival compared with
those who did not (P=0.05). The results of the study have
been analysed by disease site, extent of primary tumour (T),
nodal status (N), age, sex and degree of differentiation of
tumour. Nodal status was the most significant prognostic
factor in patients with advanced disease.
Salvage surgery following combined chemotherapy and
radiotherapy
W.G. Edwards, H.R. Grant & J.S. Tobias
SECOG Trial, CRC Clinical Trials Centre, London, UK.
One hundred and twenty-six patients have undergone salvage
surgery following primary treatment with chemotherapy and
radiotherapy for stage 3 or 4 squamous carcinoma of the
head and neck. The SECOG trial design and 5 year survival
data on 429 patients entered is itemised by primary site and
chemotherapy arm.
Surgery was limited to histologically proved persisting or
recurrent carcinoma. Fifty-four patients received synchro-
nous, and 72 received sequential treatment using VBM or
VBMF with full dose megavoltage radiotherapy.
Details of primary site, TNM status, allocated treatment
and results of surgery in all 126 patients are itemised. Five
year postoperative survival is 33% and a highly significant
trend (P=0.002) in favour of the older patients is reported.
The range of surgical excision and reconstruction carried
out with early postoperative mortality is itemised for this
prospective study maintaining complete follow up.
The role of microorganisms in osteoradionecrosis of the
mandible
I.L. Hutchison & C.C. Kibbler
Joint Department of Maxillofacial Surgery, Eastman Dental
and University College Hospitals, and Clinical Microbiology,
University College Hospital, London, UK.
Two theories for the pathogenesis of osteoradionecrosis of
the mandible (ORN) predominate: Firstly, that ORN is
analogous to osteomyelitis with microorganisms playing a
central role in bone destruction; secondly, that ORN is an
aseptic ischaemic necrosis, mediated by endarteritis obliter-
ans, in which microorganisms merely act as superficial
contaminants. This study sought to clarify the role of
microorganisms in ORN.
Twelve patients with ORN defined as 'an area of exposed
mandible in a previously irradiated field that fails to heal for
two months' underwent corrective surgery. Bone was
debrided until bleeding trabeculae were encountered, and in
some cases the residual mandible was covered with local
vascularised flaps. The bone removed was collected in plain
sterile pots, and jars of Robertson's cooked meat medium. It
was then cultured on neomycin blood agar for anaerobic
bacteria and Actinomyces species, and on Sabouraud's
medium for Candida species, in addition to routine culture
on blood agar.
A mixed growth of mouth flora was cultured from the
bone in eight cases, Candida species in three cases and
Actinomyces species were not isolated despite prolonged
anaerobic culture. Soft tissue specimens grew Staphylococcus
aureus in three cases, Group G Streptococcus in one case, and
anaerobes in one case. Histology specimens showed no
permeation of the medulla with microorganisms.
Our results suggest that ORN is not primarily an infective
osteomyelitis in which bone destruction progresses rapidly
through the medullary cavity, although microorganisms are
present. This has important implications for the management
of ORN.
Single fraction radiotherapy for carcinoma of the skin
S. Chan, J.Lim & R. Hunter
Christie Hospital and Holt Radium Institute, Manchester,
UK.
Single fraction radiotherapy using superficial X-ray machine
has obvious advantages in the treatment of small superficial
carcinomas of the skin. We have studied retrospectively
1,005 cases of basal cell carcinoma and squamous cell
carcinoma of the skin, treated by a single fraction X-ray
therapy in 1976 in this institution to define the tumour
recurrence and late radiation necrosis rates with treatment
using different radiation doses and different field sizes.
Three radiation doses were used: 22.5 Gy, 20 Gy and
18Gy. All cases were treated by superficial X-ray machine at
45kV or 100kV (10cm FSD). The cumulative recurrence
rate after 10 years of follow-up was 4.4%. The cumulative
late radiation necrosis rate was 6% (17% required surgical
repair). The relationship between field sizes/radiation dosages
and recurrence/necrosis rates were as follows:THIRD MEETING OF THE BRITISH ONCOLOGICAL ASSOCIATION 521
Diameter of radiation portal (cm)
1.5-2.0 2.1-3.0 3.1-4.0 4.1-5.0
(N=531) (N=415) (N=42) (N=17)
Recurrence (%) 4 4 7.7 9.1




Recurrence (%) 5.1 4.6 4.1
Necrosis (%) 2.3 3.0 9.6
These results demonstrate the acceptability of single fraction
X-ray therapy for the treatment of these superficial skin
cancers, and provide useful clinical criteria for the appli-
cation of this therapeutic technique. The optimal dosage in
this series of treatments seems to be 20Gy with a maximum
field size of 3.0cm diameter.
Conference Lecture
Clinical prospects for hyperthermia
J. Overgaard
Danish Cancer Society, Department of Experimental Clinical
Oncology, Aarhus, Denmark
Using hyperthermia as an adjuvant to radiotherapy in the
treatment of especially locally advanced tumours is based on
a well developed biological rationale. A large number of
early clinical studies of superficial tumours (e.g. advanced
breast, chest wall recurrences, neck nodes, and malignant
melanoma) have confirmed this biological rationale. Clinical
data have been collected in an attempt to evaluate the
potential benefit. An analysis of this material has demon-
strated iso-effective thermal enhancement ratios of -1.5 in
the investigated tumour sites. The place for hyperthermia in
oncology is, however, still not defined because the heating
technique as yet generally is unsatisfactory and conclusive
results of controlled clinical trials still are not available.
Nevertheless, hyperthermia appears to be a helpful tool in
palliative treatment and persistent tumour control has been
obtained in tumours recurring in previously irradiated sites.
This effect has especially been pronounced when using a
combination of interstitial hyperthermia and irradiation. The
clinical evaluation has almost solely been limited to superfi-
cial tumours whereas external heating of deep-seated
tumours is still preliminary and most studies are in Phases I-
II with emphasis on toxicity and feasibility. Initial results are
promising with regard to improved tumour control and
acceptable toxicity.
Although hyperthermia is used clinically, the optimal
treatment schedule has not yet been defined and there are
significant problems related to fractionation of both hyper-
thermia and radiation, application of homogeneous heating,
and definition of a thermal dose concept. The implications
of these problems for a potentiation and optimization of the
clinical application will be discussed.
Proffered papers
Breast Cancer I
Cellular DNA changes during the genesis of breast cancer
R. Carpenter, J. Matthews, K. Gotting, R. Nicholson &
T. Cooke
Charing Cross Hospital, London; Royal Liverpool Hospital,
Liverpool and Tenovus Institute, Cardiff, UK.
There are no histological features which predict the biologi-
cal behaviour of pre-malignant and pre-invasive breast
lesions increasingly detected as a result of breast screening.
We have investigated changes in cellular DNA content,
proliferation index (PI) and ploidy during the evolution of
carcinogen induced rat mammary carcinoma.
Following intragastric installation of dimethylbenz-
anthracene, or saline as control, breast tissue was sampled at
2-weekly intervals, disaggregated, feulgen stained and PI and
ploidy assessed using integrating microdensitometry.
Glandular hyperplasia present in 45% of glands was seen
more frequently than in controls by the second week of
treatment (P<0.01). Mean PIs of 7 and 9% were signifi-
cantly higher in induced breast at 2 and 4 weeks relative to
control values of 4.6 and 3.7% (P<0.04 and P<0.03
respectively). Aneuploid profiles, never seen in controls, first
occurred at 4 weeks in 33% of glands, rising to a maximum
of 54% by 6 weeks. Carcinoma, evident at 6 weeks, occurred
in up to 50% of glands, but was preceded by aneuploidy and
abnormally high PI in all cases (r=0.86; P<0.05 and
r=0.98, P<0.01 respectively).
In this animal model quantitative changes in cellular DNA
content precede the appearance of carcinoma, indicating the
potential benefit of similar assessment of human pre-invasive
breast lesions.
Regulation of epidermal growth factor receptor synthesis in
breast cancer cells
R.E. Leake, W.D. George, D. Godfrey & F. Rinaldi
Departments of Biochemistry and Surgery, University of
Glasgow, Glasgow G12 8QQ, UK.
Growth regulation of oestrogen receptor (ER) positive cells
was thought to be mediated by a direct effect of activated
ER complex on the target epithelial cell. Experiments using
both primary cell cultures and the ER+ breast cancer cell
lines MCF-7 and ZR-75 show a maximum stimulation of
oestradiol alone of 50-70% over 4 days in phenol-red
containing medium. A combination of prolactin and epider-
mal growth factor (EGF), under identical conditions, gives a
stimulation of 250%. If prolactin is given alone, there is little
growth stimulation but the level of available EGF receptor
rises by 10-fold over the 4 day growth (expressed per unit
DNA). Similar experiments in phenol red-free medium (phe-
nol red contains a weak oestrogen) indicate that exogenous
oestradiol (at physiological levels) is required to promote the
full effect of prolactin on synthesis of EGF receptor. Cyclo-
heximide (at levels which do not alter control growth rates)
completely inhibits the increase in available EGF receptor.
Progestins have a significant but smaller effect on both
growth rates and EGF receptor synthesis.
Separate experiments show that -45% of breast cancer
biopsies contain significant levels of EGF receptor, measured
by a ligand binding assay. However, test of the correlation
between extractable EGF (range 0-45ngml-i) and content
of EGF receptor proved negative. EGF receptor-mediated
growth in vivo may be due to TGFa in breast cancer cells. A522 THIRD MEETING OF THE BRITISH ONCOLOGICAL ASSOCIATION
satisfactory assay for tissue content of TGFax is still being
developed. Blockage of EGF receptor may have an anti-
tumour activity.
Predictors of local recurrence and progression in patients
treated by surgery alone for in situ breast carcinoma
P. Price, G. Walsh, R.P. A'Hern, B. Gusterson,
H.D. Sinnett, J.R. Yarnold & J.A. Mckinna
The Breast Unit, The Royal Marsden Hospital, Fulham
Road and The Institute of Cancer Research, Sutton, Surrey,
UK.
At the Royal Marsden Hospital, between 1972 and 1982, 62
patients were treated by surgery alone for histologically
proven pure duct carcinoma in situ (DCIS). Patients were
treated either by mastectomy (21), subcutaneous mastectomy
(4), or by local excision with clinical and mammographic
follow-up (37). Median follow-up was 7 years (range 5 years-
14 years). Twenty-four of 62 (39%) patients have recurred
locally. Median time to recurrence was 28 months (range 6
months-86 months). Local recurrence on the chest wall
occurred in 1/21 (5%) patients having mastectomy and in
the chest wall or nipple in 3/4 (75%) patients having sub-
cutaneous mastectomy; 20/37 (54%) patients recurred locally
in the breast after conservative surgery and most recurred at
or near the original site of disease. Twelve of 24 (50%)
patients recurred locally with invasive disease and 2/38 (5%)
patients without local recurrence developed metastases.
On univariate analysis, there was a suggestion that
patients with an incomplete excision were more likely to
recur (hazard ratio 2.6 95% CI 0.82-6.05 P=0.1). The
factors which correlated with local recurrence on multi-
variate analysis were conservative surgery (hazard ratio 7.69
95% CI 1.01-50 P=0.02) multifocal disease (hazard ratio
2.40 95% CI 0.97-5.97 P=0.06); histological sub-type of
disease - papillary tumours were less likely to recur (hazard
ratio 0.07 95% CI 0.01-0.40 P=0.002). Conservative surgery
was the only factor to correlate with invasive local recur-
rence (hazard ratio 7.14 95% CI 0.88-50.0 P=0.07),
although this did not reach conventional statistical
significance.
Does chemotherapy improve survival in advanced breast
cancer?
relationship between response rates and survival (P<0.01).
The number of patients in a comparison did not influence
this relationship.
The equation derived from linear regression allows deter-
mination of the likely survival benefit that may be achieved
by increasing response rates with more toxic regimens. This
model suggests, for example, that increasing response rates
from 20% to 40% will increase median survival by 24%, say
16 to 20 months.
Perioperative cyclophosphamide in the management of early
breast cancer: Results from two clinical trials
J. Houghton, D.L. Riley, R. Nissen-Meyer & M. Baum.
Clinical Trials Centre, Kings College School of Medicine
and Dentistry, London, UK.
Two large randomised clinical trials were designed to eval-
uate the role of a single course of cyclophosphamide
(5mgkg-1 day-1 i.v.) for 6 days immediately following
primary surgery for early breast cancer. The Scandinavian
Adjuvant Chemotherapy Study (SACS-1), initiated in 1965,
randomised 1,026 patients and has now been followed up for
twenty years. Relapse-free survival shows a consistent benefit
for patients treated with the perioperative course (X2 = 11.05,
P=0.0009). The Cancer Research Campaign Adjuvant
Breast Trial (CRC II) exactly repeated the SACS-1 trial but
in a 2 x 2 design which also allowed assessment of a two year
course of tamoxifen. The relapse-free survival at a median
follow-up of approximately 4 years shows a trend but no
significant benefit for the treated patients (X2 =3.09).
Data from the two trials have been analysed together;
relapse-free survival stratified for menstrual status gave an
overall relative risk (RR) of 0.82 (X2 =9.73, P=0.002; preme-
nopausal RR=0.83; postmenopausal RR=0.82). An overall
significant advantage was also demonstrated when the data
were stratified according to nodal status (RR=0.83,
x2-=8.71), P=0.003); the beneficial effect of cyclophos-
phamide was seen in both node negative and node positive
patients although in the latter group the result was not
conventionally significant (node negative - RR=0.78;
x2=5.85, P=0.016; node positive - RR=0.86, x2=3.45,
P=0.06).
Since the course was well tolerated by most patients,
administration of such therapy should be considered in the
management of early breast cancer patients.
S.R. Ebbs, R.P. A'Hern & M. Baum
Department of Surgery, King's College Hospital, London,
UK.
The relative efficacies of cytotoxic chemotherapy regimens in
the treatment of advanced breast cancer are generally
assessed by comparing response rates achieved in ran-
domised trials. Treatment ideally prolongs survival as well as
achieving successful palliation. Trials rarely demonstrate a
statistically significant survival advantage.
We have tested the hypothesis that chemotherapy has no
impact on survival by examining the correlation between
response rates and survival in 88 comparisons between arms
from the same trial, extracted from 53 published trials of
chemotherapy in advanced breast cancer (Powles, T.J. et al.,
Lancet, i, 580).
If there were no relationship between response rates and
survival one would expect half of the comparisons to show
improved survival associated with improved response and
half to show decreased survival with improved response.
However, in 71% of comparisons the arm with the higher
response rate also demonstrated longer median survival.
Weighted linear regression showed a statistically significant
Tumour and Normal Tissue Biology I
Why are some human tumours more radiosensitive than
others?
G.G. Steel & J.H. Peacock
The Institute of Cancer Research, Sutton, Surrey SM2 SPX,
UK.
There is now good evidence that the radiosensitivity of
human tumour cells varies from one tumour type to another,
and that the steepness of the initial part of the cell survival
curve correlates with clinical radioresponsiveness. Studies at
low dose rate allow differences between tumour cells to be
seen more clearly. Current mathematical models of radiation
cell killing include two components: A linear (i.e. exponen-
tial, 'oc-component') and a bending component ('#-
component'). Repair of radiation damage mainly affects the
fl-component. Among the 17 human tumour cell lines that
we have studied, the average surviving fraction at 2Gy due
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is 0.88. The f-effect appears to be similar in radiosensitive
and radioresistant tumours; among the radiosensitive
tumours the #-effect makes a very small contribution to
overall radiosensitivity. Therefore the differences between
radiosensitive and radioresistant tumours must be looked for
not in repair capacity but in the nature of the a-component.
Cellular radiosensitivity in human tumour cells is determined
by initial DNA damage
A.M. Cassoni, L.R. Kelland, T.J. McMillan, J.H. Peacock &
G.G. Steel
The Institute of Cancer Research, Sutton, Surrey, UK.
For some years it has been considered that radioresponsive-
ness of tumour cells is closely related to their recovery
proficiency. More recently, on the basis of studies in murine
systems, it has been suggested that the level of induced
damage, rather than differences in its repair, may be impor-
tant (Radford, 1986).
We have therefore set out to analyse the extent to which
the level of damage induced by irradiation correlates with
radiosensitivity in a wide range of human tumours. Nine
tumours of differing radiosensitivity were investigated. DNA
damage, as double strand breaks (dsb) was measured using
neutral filter elution immediately after irradiation at ice
temperature and compared with cellular survival obtained by
soft agar and monolayer colony forming assays.
The slope of the dsb-induction curve reflected the shape of
the corresponding survival curve, with two distinct patterns
being seen. In the five most sensitive lines (mean survival at
2Gy, 0.3) dsb induction was linear with dose. In the four
more resistant lines (mean survival at 2Gy, 0.6) dsb induc-
tion was biphasic with an initial shoulder. Between the
groups a two-fold difference in dose was required to produce
the same DNA damage at doses within the survival range.
These data suggest that differences in radiosensitivity are
related to differences in damage induction, without the need
to postulate differences in repair capacity.
Radiation induced cell death by chromatin loss: A model to
explain the shape of cell survival curves
I.R. Campbell & H.M. Warenius
University of Liverpool Cancer Research Campaign,
Department of Radiation Oncology, Clatterbridge Hospital,
Wirral, Merseyside, UK.
Many models have been proposed to explain the relationship
between dose of low LET radiation and cell survival. Most
of these have utilised hypothetical concepts such as specific
intracellular targets for which there is no firm biological
basis. The Chadwick-Leenhouts model does have a biologi-
cal basis of single and double strand DNA breaks, but only
fits the infrequent situation of a continuously curving cell
survival function.
We propose an alternative model which relates repro-
ductive death of cells by radiation to loss of chromatin at
cell division. This loss of chromatin can occur through
chromosomal deletions or through the formation of asym-
metrical chromosomal exchanges. It is proposed that smaller
doses of radiation produce fewer chromatin breaks, which
are more likely to be accurately repaired, compared to larger
doses. Consequently, smaller doses of radiation are less
efficient in causing cell death, leading to a shoulder on the
cell survival curve. Much experimental evidence is in support
of this model, and the fit between the derived formula
described in this paper and experimental cell survival curves
is good. The derived formula approximates to the linear-
quadratic equation at low doses of radiation.
Strategies for the evaluation of drug resistance in human
tumour cells
S.A. Morgan, J.V. Watson & P.J. Smith
MRC Clinical Oncology and Radiotherapeutics Unit, MRC
Centre, Hills Road, Cambridge CB2 2QH, UK.
Mechanisms of chemotherapeutic drug resistance which have
been identified in vitro include modified cellular uptake/
retention of drug (e.g. membrane changes leading to multi-
drug resistance: MDR) and variation in intracellular target
molecules, e.g. DNA topoisomerase II (topo II) modifica-
tions conferring resistance to topo II-interactive drugs such
as VP16-213 and m-AMSA. We have evaluated techniques
for the identification of such mechanisms in a human small
cell lung cancer (SCLC) line (NCI-H69/P), its in vitro-
derived resistant variant (NCI-H69/LX4), and fresh human
tissue obtained by lymph node biopsy of 3 patients with
SCLC. Uptake of the DNA-specific fluorochrome, Hoechst
dye 33342 (Ho342) (which mimics in its cellular exclusion
properties the uptake and loss of drugs involved in MDR)
was assessed using flow cytometry (FCM) allowing quantita-
tive measurement of DNA-Ho342 interaction, and identifica-
tion of subpopulations of cells within biopsy material. Topo
II-DNA cross-linking activity was assayed in nuclear protein
extracts using mAMSA and VP16. Results with nuclear
extracts of NCI-H69/LX4 did not suggest abnormal DNA
topoisomerase expression whereas FCM analysis clearly
demonstrated reduced Ho342 uptake. This partially reversed
with the MDR modifier verapamil. Biopsy-obtained SCLC
in 2 cases showed reduced Ho342 uptake, compared to NCI-
H69/P, which could be reversed by pre-exposure to verapa-
mil, but topo II activity did not differ significantly from
H69. We conclude that FCM analysis of human tumour
biopsies can be used to evaluate drug uptake patterns with
the advantage modifier responsiveness can be quantitated
rapidly and the characterisation of tumour subpopulations
followed.
The role of glutathione metabolism in cytotoxic drug
resistance, and cross-resistance to radiotherapy -
Implications for combined modality treatment
R.A. Britten & J.A. Green
CRC Department of Radiation Oncology, Clatterbridge,
Wirral, UK.
The use of sequential cytotoxic chemotherapy and radio-
therapy, following adequate surgical debulking of advanced
human ovarian carcinoma is currently under investigation in
our department. Cellular glutathione (GSH), and gluta-
thione-S-transferase (GST) are important determinants of
cellular resistance to both cytotoxic chemotherapy, and
radiotherapy. Thus prior exposure to chemotherapy, and the
associated emergence of chemoresistance, may by virtue of
elevated levels of glutathione and GST, predispose to the
development of radioresistance in tumours.
The relationship between GST, GSH, GSSG and chemo-
resistance has been established in the human ovarian adeno-
carcinoma OAW42 cell line, and a chemoresistant sub-line,
OAW42/MER. The resistant OAW42/MER line was 2-fold
more resistant to melphalan compared to the parent OAW42
cells. BSO potentiated melphalan cytotoxicity by 2-5-fold,
while OTZ reduced cytotoxicity by 1.5-2-fold. The response
of the melphalan sensitive and resistant OAW42 and 2780
cell sub-lines to photon and neutron irradiation is at present
under investigation.
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Concurrent with this work a prospective study of GSH
and GST levels in normal and malignant human ovarian
biopsies has been undertaken. Preliminary results from 22
patients would suggest elevated GSSG and GST levels in
tissue from pre-treated patients, and in those biopsies which
are hyperdiploid. Altered thiol metabolism may therefore
account for the failure of treatment approaches employing
sequential chemotherapy and radiotherapy.
Proffered papers
Breast Cancer II
British Oncological Association Lecture
The genetics of colorectal cancer
W.F. Bodmer
Imperial Cancer Research Fund, London, UK.
Familial adenomatous polyposis (FAP- also called familial
polyposis coli) is a rare dominantly inherited susceptibility to
colon cancer. Following up a case report of an interstitial
deletion of chromosome 5 in a mentally retarded individual
with multiple developmental abnormalities and FAP we have
shown that the FAP gene is on chromosome 5, most
probably near bands 5q21-5q22. Subsequent studies by
others have confirmed this linkage and the data suggest that
the probe (Cl1 P11) may be less than 2% recombination
away from FAP. This now provides the basis for the use of
long range DNA analysis techniques to isolate the FAP
gene.
In a parallel study following the approach of Cavanee et
al. highly polymorphic probes on chromosome 5 were used
to search for allele loss in sporadic tumours as compared to
normal tissue from the same individual. The data showed
that at least 20% and possibly up to 40% of sporadic
colorectal tumours become homo- or hemizygous for
chromosome 5 markers, indicating that the FAP gene
becomes recessive in a relatively high proportion of colo-
rectal carcinomas. This is the first clear example of a
recessive genetic defect in one of the commonest cancers.
Polyps from FAP patients do not show chromosome allele
loss. The discovery of dominantly acting oncogenes control-
ling growth factors or their receptors or regulators of their
expression, and of recessive genetic defects which may exert
dominant control over differentiation through appropriate
receptors and ligands suggests a general scheme that can
explain many aspects of dominant and recessive action at the
cellular level in the development of tumours.
Altered fractionation in early breast cancer - a randomised
trial
J.R. Owen and M.B. Barton
Radiotherapy Department, Cheltenham General Hospital,
Cheltenham, Glos., UK.
Local excision and radiotherapy have become the treatment
of choice in early breast cancer. Approximately 80% of new
cases are eligible and this proportion may increase with the
advent of screening services. With the greatly increased load
on radiotherapy departments some centres are already using
3 fraction/week or 5 fraction/fortnight regimens despite
theoretical evidence to suggest an adverse effect on late
tissue damage from a larger dose-per-fraction size. Psycho-
logical morbidity may also be affected by the number of
visits to a radiotherapy department. There has been no
prospective clinical test of this policy.
We report a prospective trial of lumpectomy followed by
irradiation of the whole breast and lymphatics. Two hundred
and eleven patients were randomised to receive one of three
regimens, each with a TDF of 70;
1. 45.00Gy in 25 fractions over 5 weeks
2. 40.00Gy in 15 fractions over 5 weeks




All then received a boost to the primary (16.00Gy), axilla
(10.00 to 16.00 Gy) and IMC (10.00 Gy). With a median
follow-up of 2.6 years there is no significant difference in the
actuarial survival, disease-free survival or local control rates.
Cosmesis was assessed with an observer based 4 point scale.
While the percentage with a poor score gradually increased
with time there was no significant difference between the 3
treatment groups. There was a slightly higher rate of arm
oedema in the 39Gy group (8/71) but only in comparison
with the 40Gy group (1/71) was this of borderline signifi-
cance (0.01 <P<0.05).
Within the limits of the power and design of this study no
clinically significant difference has been shown between the 3
fractionation regimens. We are now undertaking a further
prospective randomised trial to better define the nature of
any late changes in cosmetic and psychological outcome.
Influence of breast size on late radiation reaction
A.Y. Rostom & J. Brierley
Radiotherapy Department, St. Luke's Hospital, Guildford,
Surrey, UK.
Late radiation reactions were assessed in 129 patients with
clinical stage I and II breast cancer. The primary treatment
consisted of wide local excision and radiotherapy. Four
fields were used, i.e., supraclavicular and anterior axillary,
parasternal and a pair of glancing fields to the breast. A
maximum dose of 4,875cGy was given in 15 fractions over
39 days. Assessment of late reaction was made 26/120
months from the end of radiotherapy. Brassiere size (cup
and bust) at the time of radiotherapy was known for all
patients. The cosmetic appearance and breast consistency
was graded as: grade I normal, grade III severe distortion,
i.e., in appearance and consistency, grade II moderate, i.e.,
any reaction between I and III.
No severe reaction was seen. There was no significant
difference in the incidence of reaction in relation to cup size.
However, there was highly statistical significant difference in
the incidence of reaction in relation to bust size. No
reactions were noted in women with brassiere size of 36A or
under. Moderate reaction was noted in 6 out of 42 patients,
brassiere size 36B-36D and in 16 of 44 patients, brassiere
size 38A and over. We are continuing to use this fractiona-
tion for women with brassiere sizes up to 36B. Women over
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A prospective randomised trial comparing bolus with
prolonged infusion of epirubicin for advanced breast cancer
S.R. Ebbs, H. Graham, T. Bates & M. Baum
Departments of Surgery, King's College Hospital, London
and William Harvey Hospital, Ashford, Kent, UK.
It has been proposed that prolonged exposure to cytotoxics
will improve the therapeutic index by avoiding high drug
levels associated with toxicity and also by increasing cell kill
of cycle specific agents. We have treated this hypothesis in a
clinical trial.
Sixty-two women were randomised to receive weekly single
agent chemotherapy (epirubicin) for advanced breast cancer
by either bolus injection or prolonged intravenous infusion




response 11(46%) 3 (13%) P=0.03a
Nausea or vomiting 13 5 P=0.02a
Myelosuppression 8 5 NS
Alopecia 14 6 P=0.04a
aChi-square test with Yates continuity correction.
Both survival and time to treatment failure were worse for
the infusion arm (P=0.005, P=0.07*).
Whilst infusion therapy reduces side effects of epirubicin it
does so at the expense of a loss of efficacy.
*Peto log rank test.
Comparison of outcome between mastectomy and
lumpectomy patients in an Irish survey of breast cancer
M.W.H. Timms', D. Hollywood2, M. Moriarty2 &
J. Cullen3
'Newcastle Hospital, Greystones, Wicklow; 2St. Luke's
Hospital, Dublin 6; and 3Psychomatic Unit, St. James's
Hospital, Dublin 8, Eire.
The paper reports data from a study of breast cancer
patients attending a radiotherapy department. The method-
ology is presented, outcome being measured using both a
patient self-report inventory (the psychosocial adjustment to
illness scale) and observer ratings (the Spitzer quality of life
index). The data relating to surgical intervention is then
presented. A group of 100 patients seen as consecutive
attenders at a radiotherapist's clinic were interviewed: the
sample was varied as to age, elapsed time since diagnosis,
and present clinical state (new, clear, recurrent). A higher
proportion of mastectomy patients were of lower socio-
economic status and from rural areas (more remote from the
treatment centre). There were no differences in self-rated
psychological distress between those from the mastectomy
and those from the lumpectomy groups. However, the
lumpectomy patients had a better quality of life rating, in
spite of the fact that, as a group, they had had their surgery
in the more recent past.
Does radiotherapy for breast cancer produce psychiatric
morbidity?
K. Barltrop & K.R. Durrant.
Departments of Community Medicine and Radiotherapy and
Oncology, Radcliffe Infirmary and Churchill Hospital,
Oxford, UK.
Prognosis following omental transportation for locally
advanced and recurrent breast cancer
R.J.L. Williams & H. White
The Royal Marsden Hospital, London, UK.
An analysis was carried out of 43 patients undergoing
omental transposition for locoregional problems associated
with breast cancer. Indications for surgery included
advanced primary tumour (5), recurrent tumour (32), radia-
tion induced sarcoma (2), and radionecrosis (4). Tumours
were typically extensive (mean diameter 7.2cms) and skin
ulceration affected 30 of these cases. Other treatment modal-
ities had for the most part been exhausted.
Surgical excision followed by reconstruction using trans-
posed omentum resulted in worthwhile local control and
symptom relief in 31 patients (median duration 22 months).
Chest wall disease rapidly recurred peripheral to the omental
graft in 12 patients. On multiple regression analysis, duration
of local control was related to tumour diameter (P<<0.001),
ulceration (P<0.005), earlier radioresistance (P<0.02), and
the time elapsed from cancer diagnosis to operation
(P<0.1). Survival (median 21, range 1.5-122 months) cor-
related with tumour size (P<0.001), prior chemotherapy
(P<0.01), and early re-recurrence (P<0.005).
Omental transfer provides a reliable basis for restoring
epithelial cover after radical surgery, particularly useful after
previous irradiation injury. Applied to advanced and recur-
rent breast cancer, an aggressive surgical approach signifi-
cantly improved the quality of life of most patients. Careful
case selection is required to avoid pointless surgery in
irremediable tumours.
Patients with early breast cancer are highly prone to severe
anxiety, depression, and sexual problems. The psychiatric
morbidity of breast surgery has previously been evaluated.
This study was undertaken to determine the pattern and
degree of physical and psychiatric morbidity associated with
radical radiation therapy for early breast cancer.
Twenty-nine patients with early operable breast cancer
were assessed. Fourteen had undergone mastectomy and 15
had been treated by wide local excision. Anxiety and
depression were assessed using the Leeds Self-Assessment
Scale, the Spielberger State-Trait Anxiety Inventory, and the
MRC General Health Card, which also was used to deter-
mine physical side-effects.
Twenty-eight percent of patients were clinically anxious or
depressed before the start of radiotherapy, 17% at three
weeks post-radiation, and 24% at three months. State
anxiety was highest at the beginning of the course. Although
psychiatric morbidity in patients undergoing irradiation for
breast cancer is high, the results of this study do not support
the concept that radiotherapy per se increases the incidence
of clinically significant anxiety or depression.
Genito-urinary Cancer
Tumour proliferation rate as a predictive factor in testicular
teratomas
P. Price, S.J. Hogan & A. Horwich
Institute of Cancer Research and Royal Marsden Hospital,
Surrey, UK.
At the Royal Marsden Hospital, between 1984 and 1987, 158
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using BEP combination chemotherapy (bleomycin, etoposide
and cisplatinum) as first line treatment. Twenty (13%)
patients have died. Tumour proliferation rates prior to
chemotherapy measured by the rate of rise of tumour
marker production (TMP) were calculated and correlated
with prognosis. One hundred and nine of 142 (76%) patients
were serum marker positive, either for HCG, AFP or both.
Fifty-four patients had three or more sequential serum
marker levels recorded after orchidectomy and before the
start of chemotherapy from which the change in rate of
TMP per day by the tumour could be determined. The rate
of TMP (IU/L/day) took into account the continuing clear-
ance of marker from the serum. The rate of TMP rise was
exponential. The rate of this rise was expressed as the rate of
marker production doubling time and is a measure of the
tumour proliferation rate.
Rates of marker production doubling time varied from 0.5
days to 43 days (34 cases) for AFP and from 3 days to 27.5
days (25 cases) for HCG. The doubling times appeared to be
independent of the tumour stage. In the AFP marker group
three patients died and all had doubling times 06.5 days
(P=0.136). In the HCG marker group, four patients died
and all had doubling times <5.2 days (P=0.0226). Rapid
tumour proliferation rates reflected by short TMP doubling
times may carry a poor prognosis in patients with testicular
teratomas treated by chemotherapy.
BEP chemotherapy for metastatic teratoma: Royal Marsden
Hospital experience 1979-1986
D.P. Dearnaley, J. Nicholls, M. Saunders, M.J. Peckham,
W. Hendry & A. Horwich
Institute of Cancer Research and Royal Marsden Hospital,
Sutton, Surrey, UK.
One hundred and twenty-eight previously untreated patients
with metastatic testicular teratoma have been given BEP
chemotherapy (cisplatinum 20mgm-2 days 1-5, etoposide
120 mgm-2 days 1-3, bleomycin 30mg days 2, 9, 16)
between 1979 and 1986. Mean follow up from commence-
ment of treatment is 51 months (range 14m-84m). The
Royal Marsden Hospital staging system was used and
patients divided into prognostic groups as defined by the
MRC working party (Lancet, 1985). Ninety cases had small
volume (15 with high markers), 22 cases large volume (10
with high markers) and 16 very large volume disease (10
with high markers).
Disease free/survival results are for small volume disease,
94%/99%; large volume disease 73%/73%; very large
volume disease 25%/31%. Residual masses were resected in
50 patients. White count nadir <1,000mm-3 occurred in
3%, platelet nadir <50,000mm-3 in 2% and Hb <9.5g
100ml-1 in 15% of 482 chemotherapy courses. Septicaemia
occurred in 4 patients with 1 fatality. Symptomatic bleomy-
cin lung damage was reported in 22 patients. Steroid treat-
ment was necessary in only 4 cases, with one death. Mean
fall in EDTA renal clearance after 4 courses of chemo-
therapy was 26mlmin-' (range +78 to -81mlmin-1).
Twenty-four pregnancies have produced 21 normal offspring.
The identification of risk related factors has enabled the
design of chemotherapy regimes of reduced toxicity in good
prognostic groups, whilst intensifying treatment in high risk
cases. This series will permit future comparison with such
sequential studies.
A multicentre randomised trial comparing the LHRH agonist
'zoladex' with 'zoladex' in combination with flutamide in the
treatment of advanced prostate cancer
F. Daniel & C.J. Tyrrell
Department of Radiotherapy, Freedom Fields Hospital,
Plymouth, U.K, on behalf of the 'International Prostate
Cancer Study Group'
Between April 1986 and May 1987, 562 patients were
recruited from ten countries into a multicentre, randomised
trial comparing 'zoladex' with a combination of 'zoladex'
and the nonsteroidal antiandrogen flutamide. 'Zoladex' was
administered as a depot injection every 28 days and fluta-
mide was given as three 250mg tablets daily.
Patients with histologically confirmed locally advanced
(T3/T4) or metastatic (M1) carcinoma were included.
Previous hormone therapy, anti-hormone therapy,
chemotherapy or patients having had an orchidectomy
were excluded.
Fifty-five percent of the patients had Ml disease, the
remaining being locally advanced disease. The two groups
were balanced between major demographic parameters (T
category, histology, metastases, performance status, etc.).
The median duration of follow up is 34 weeks in the
zoladex group and 28 weeks in the combined treatment
group.
The objective and subjective response rates are similar in
both groups, but the median time to treatment failure is
significantly longer in the zoladex group, largely due to the
greater number of withdrawals because of the adverse re-
action from the combined treatment (P=0.004).
Accelerated fractionation (AF) for bladder cancer
A. Horwich, G. Duchesne, D. Dearnaley & G.G. Steel
The Institute of Cancer Research and the Royal Marsden
Hospital, Sutton, Surrey, UK.
A pilot study was performed to define the acute toxicity of
AF in the radical treatment of bladder cancer. Treatment
was in 2 phases, treating the bladder to 60-64Gy in 30-32
fractions over 4 weeks and the upper pelvic nodes to 44Gy
in 22 fractions over 4 weeks. The schedule employed 2
fractions per day on 16 treatment days, with a minimum of a
6 hour gap between fractions. Of 16 patients entering the
study, 15 completed radiotherapy according to protocol. One
developed subacute bowel obstruction after 44Gy, which
was managed conservatively. The pattern of toxicity in the
other patients was as follows: Mild diarrhoea in 11/15 (73%)
typically lasting 3 or 4 days in the 2nd week of treatment
and 7-10 days following completion; frequency of micturi-
tion with nocturia > x 5 in 10/15 (67%) and dysuria in 7/15
(47%) appeared during the 4th week and lasted 1-2 weeks
after the end of treatment. The only non-transient toxic
reaction has been in a further patient who had relatively
mild side effects during radiotherapy but who developed
subacute bowel obstruction 2 months later, which was
treated by defunctioning colostomy. The median follow up
following AF is 6 months and it is too soon to define late
side effects, though none have yet been seen.
It seems likely that AF is associated with increased acute
reactions but the schedule of 64Gy in 32 fractions in 4
weeks was tolerated by most patients, and should be investi-
gated in a prospective randomised trial.THIRD MEETING OF THE BRITISH ONCOLOGICAL ASSOCIATION 527
Risk factors for predicting response of metastatic transitional
cell carcinoma to chemotherapy
R.T.D. Oliver, R. Iles, D. Crosby & J.P. Blandy
The London Hospital Medical College, UK.
One hundred and eight patients (previously untreated with
chemotherapy and having bidimensionally measurable meta-
static urothelial malignancy) have been entered into sequen-
tial chemotherapy trials between 1977 and 1988. Complete
response occurred in 1 of 23 receiving methotrexate
(M), 0 of 15 receiving cisplatin (P), 0 of 20 receiving carbo-
platin, 3 of 20 receiving M+P, 5 of 12 receiving M+
vinblastine+P, and 2 of 8 receiving M +V+adriamycin +P.
Overall complete plus partial response rate was higher in the
M+P, MVP and MVAC groups (75%), though so was
toxicity with 35% of patients experiencing temporary major
renal failure episodes. Although WHO/UICC performance
status 3 and 4 patients had a lower incidence and shorter
duration of response, it did not provide a means of exclud-
ing patients who achieved complete remission.
Studies using serial urine cytology showed that 7 of 14
responders had complete loss of malignant cells from the
urine compared to none of 21 non-responders and there was
a suggestion that duration of overall clinical response was
longer in those showing a cytological response. Another
factor influencing response was expression of BhCG. Ele-
vated serum levels of BhCG were found in 1 of 18 TlMO, 0
of 23 T2,3,4 MO, 0 of 4 TxNI-4M0, and 9 of 12
TxNxMl tumours. None of 9 who were BhCG positive
N x Ml patients responded to chemotherapy, in contrast to 3
of 4 with BhCG negative lymphnode metastases and 2 of 3
with BhCG negative distant metastases.
Outcome of radiotherapy randomization in the Third
National Wilms' Tumour Study (NWTS-3)
P.R.M. Thomas, M. Tefft, G.J. D'Angio & P. Norkool
For the National Wilms' Tumour Study Committee,
Philadelphia, USA.
In NWTS-3, patients with stage II favourable histology (FH)
tumours were randomized to receive either no radiotherapy
(RT) or 2,000cGy to the tumour bed postoperatively. Stage
II FH children were randomized between 1,000cGy and
2,000cGy. RT boosts were allowable but given to only 6 of
280 (2%) stage III and none of the 280 stage II patients. For
both stages there was also a chemotherapy (CT) randomiza-
tion to either intensified actinomycin D (AMD) plus vincris-
tine (VCR) or to less intensive AMD plus VCR plus
doxorubicin (ADR). No statistically significant differences
were noted for abdominal relapses or disease-free survival
between any RT set. Stage III patients treated with three
drugs had a borderline statistical advantage for disease-free
survival (P=0.06). We conclude that 1,000cGy is enough for
stage III patients if three drugs are used.
Haematological Neoplasia and Sarcomas
The BNLI study of LOPP vs. LOPP/EVAP in advanced
Hodgkin's disease - a progress report
G.V. Hudson & B.W. Hancock
For the British National Lymphoma Group, UK.
Previous BNLI studies in advanced Hodgkin's disease have
shown: (1) MOPP is more effective than MOP (prednisone
omitted), (2) addition of bleomycin to MOPP is of no
benefit, (3) maintenance with CCNU (lomustine), vinblastine
and bleomycin is of no benefit and (4) LOPP (leukeran
substituted for mustine) is as effective yet much less toxic
than MOPP.
In the current study in advanced Hodgkin's disease started
in June 1983, patients are randomised to LOPP or LOPP
alternating with EVAP (etoposide, vinblastine, adriamycin,
prednisolone). Over 400 patients have been entered so far;
317 are included in this analysis. The CR rate is better for
LOPP/EVAP than for LOPP (69 and 60% respectively) as is
the actuarial percentage disease-free survival at two years (60
and 44% respectively; P<0.05). This advantage in favour of
the alternating regimen does not appear to be due to a lower
frequency of poor prognostic factors in this arm compared
to the LOPP arm. The difference was maintained for other
acknowledged individual prognostic factors. At present there
is no survival advantage from the alternating treatment
(84% overall survival at 2 years in both arms). Apart from
an increased infection rate associated with more severe and
unpredictable myelosuppression, and invariable alopecia, the
LOPP/EVAP regimen has been well tolerated by most
patients.
Hemi-body irradiation for melphalan resistant multiple
myeloma: Experience in 41 patients
C.R.J. Singer, J.S. Tobias, F. Giles & J.D.M. Richards
Departments of Haematology and Radiotherapy, University
College Hospital, Gower Street, London, UK.
Treatment of patients with resistant myeloma is often diffi-
cult because age and physical condition often restricts their
ability to tolerate more intensive chemotherapeutic regimens.
We describe our experience of hemi-body irradiation [HBI]
in 41 patients with resistant multiple myeloma.
Patients were staged using the MRC prognostic criteria: 2
patients were in group I, 18 patients in group II and 21
patients in group III. Age and sex distribution were similar
in each group. Each group had received similar amounts of
chemotherapy prior to HBI (median 8 courses of melphalan
and prednisolone), 10 patients had also failed second line
chemotherapy. Twenty-three patients had previously received
local radiotherapy. Hemi-body irradiation was administered
using a single fraction cobalt source at a dose rate of
0.25Gymin-i at median doses of 7.5Gy (upper half) and
9Gy (lower half) with a median interval of 9 weeks in those
receiving double HBI. Seventeen patients had double HBI,
only 1 patient in whom a second treatment was planned
refused it and 3 deteriorated before it could be carried out.
Twenty-one of 23 evaluable patients had a significant IgG
or IgA paraprotein response which was better in those
patients undergoing double HBI (54% >50% reduction).
Subjective improvement was reported in 69%, Bence-Jones
protein disappeared in 5 patients and immune-paresis nor-
malised in 2 following HBI. A median survival of 17 months
was obtained in group II patients but only 3.5 months in
group III. Both patients in group I survive in plateau phase
more than 40 months after HBI. Side effects were predict-
able. HBI is effective salvage therapy in resistant myeloma.
Bone marrow transplantation for acute myeloid leukaemia
C.R. Hamilton, A. Barrett & R. Powles
The Royal Marsden Hospital, Sutton, Surrey, UK.
Between August 1977 and March 1986, 237 patients with
acute myeloid leukaemia (AML) received an allogeneic bone
marrow transplant as part of their management at the Royal528 THIRD MEETING OF THE BRITISH ONCOLOGICAL ASSOCIATION
Marsden Hospital (RMH). The actuarial 5 year survival rate
post transplantation is 35%.
Results of bone marrow transplantation
Donor Actuarial
No. marrowt Conditioning AML status surv. rate
117 matched chemo/TBI Ist remission 46% at 5 yrs
42 matched chemo/TBI not Ist remission 24% at 5 yrs
62 mismatch various various 18% at 5yrs
16 matched chemo various 310% at 2 yrs
237
Since 1978, 62 patients presenting at the RMH with AML
have achieved complete remission and have had no trans-
plant procedure performed and their actuarial 5 year survival
rate is 22%.
An analysis of results, prognostic factors and the input of
conditioning regimen on leukaemia control and morbidity
will be presented as well as views on future management.
A randomised trial of two chemotherapy regimens in
osteosarcoma
R.L. Souhami
On behalf of the European Osteosarcoma Intergroup (MRC/
UKCCSG/SIOP/EORTC/GETO) and MRC Bone Sarcoma
Working Party, UK.
From August 1983 to November 1986, 307 patients with
osteosarcoma were entered into a randomised prospective
comparison of two chemotherapy regimens. Treatment A
consisted of 6 three-weekly cycles of doxorubicin 25mgm-2
days 1-3 and cisplatin 120mgm-2 day 1. Treatment B was 4
cycles of the same doxorubicin/cisplatin treatment alternat-
ing with methotrexate 8gm 2- Fifteen patients were in-
eligible. Of 292 eligible patients, 63 had metastases at
presentation and in 229 patients chemotherapy was given as
an adjuvant with surgery planned for 9 weeks after the start
of drug treatment. Thirty-five percent of patients had ampu-
tation, the rest having more conservative surgery (50%
endoprosthetic replacement). Haematological toxicity was the
same in both arms with neutropenia more prominent than
thrombocytopenia. Nausea and alopecia were almost invari-
able but equal in the two arms. Raised transaminases
occurred in 35 patients on treatment B, but none on regimen
A. At a median follow-up of 23 months median survival has
not yet been reached. In the adjuvant patients, disease-free
survival is better for the 2 drug arm (P=0.055) with no
significant difference in survival. These data imply that a
short 2 drug chemotherapy programme gives results compar-
able to the standard multidrug (TIO) regimens widely used
and this is the basis of the new randomised study started in
October 1986.
The use of radiotherapy in the management of new and
recurrent cases of soft tissue sarcomas of the limbs and limb
girdles
M.H. Robinson & C.L. Harmer
Sarcoma Unit, The Royal Marsden Hospital, London, UK.
Since 1981, 93 patients with limb or limb girdle soft tissue
sarcomas have received radiotherapy at the Royal Marsden
Hospital as part of their limb conservation treatment. Sixty-
eight were referred as new cases and 25 as recurrences with
no prior radiotherapy. Radiotherapy was given pre-
operatively in 15 new (N) and 16 recurrent (R) cases; post-
operatively in 45N and 15R; both pre- and post-operatively
in 6N and 2R and palliatively (with no definitive surgery) in
4. MFH, liposarcoma and synovial sarcomas predominated
in this series. Tumour sites included lower limb proximal-
53 cases, distal 19; upper limb proximal 9, distal 12. Surgical
clearance was graded according to Enneking and in new and
recurrent groups was intracapsular in 11 and 3 respectively;
marginal in 29N and llR; wide in 8N and 8R; radical in 6N
and 1R and uncertain or not undertaken in 14N and 2R.
Sixty-four percent of new sarcomas and 52% of local
recurrences were high grade.
Radiotherapy regimes varied between 40Gy given in 6
weekly fractions in 15 cases to 75Gy given in 60 twice daily
fractions in 4 cases. Forty-one patients received 60Gy in 30
daily fractions in 6 weeks. Median follow-up was 2 years.
Actuarial 3 year survival (80% vs. 65%) and local control
rates (80% vs. 68%) were not significantly different for new
and recurrent cases (logrank) and no significant difference in
control rates for those given pre- or post-operative radio-
therapy. All recurrences were in field except 2 which were
marginal. The role of close surgical and radiotherapy
margins, radiation dose, tumour size and grade in failure of
local control will be discussed.
Tumour and Normal Tissue Biology II
Tumour Angiogenesis: An omental bioassay
R.J.L. Williams
The Institute of Cancer Research and Royal Marsden
Hospital, London, UK.
The formation of new blood vessels is important to the
growth of most solid cancers. However, histological sections
reveal little about the mechanisms of neovascularisation and
experimental models have been limited by the lack of a
precise and reliable endothelial cell marker. Evaluation of
tumour induced vascular growth is often qualitative and
subjective. A new method of studying angiogenesis is
described.
In SWR mice, a single intraperitoneal injection of 107
Landschutz ascites cells was used to stimulate microvascular
proliferation in the gastric mesentery or omental (Lands-
chutz cells were first irradiated to prevent tumour forma-
tion). Capillary endothelial cells and their projections were
stained using a peroxidase conjugate of the plant lectin
Dolichos biflorus agglutinin.
Observed in whole mounts 30 microns in thickness, blind
ending processes or 'sprouts' were seen to arise from omental
capillaries. After tumour cell stimulation, the mean number
of capillary sprouts per omentum increased from 36.7
to 240.3 (P=0.0002). Concurrent heparin administration
produced an exaggerated sprout response (mean 396.9,
P=0.0288), while vascular sprouts were almost abolished by
i.p. hydrocortisone (mean 12.2, P<0.0001).
This 'bioassay' provides an easy and reproducible means
of distinguishing and measuring early vascular growth. The
technique can be used to investigate potential promoters and
inhibitors of tumour angiogenesis, and gives a new insight
into the morphological changes involved.
The effect of fractionation of light treatment on necrosis and
vascular function of normal skin following photodynamic
therapy.
K. Benstead, R.D. James & J.V. Moore
Paterson Institute for Cancer Research, Christie Hospital
and Holt Radium Institute, Manchester M20 9BX, UK.
Photodynamic therapy is being increasingly investigated as a
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have used fractionated light treatment although there is little
data available on the effect of this on normal tissue.
Sparing of normal tissue, mouse tail skin, by fractionation
of light treatment has been demonstrated in BDFI mice
injected with 2mg tetrasodium-meso-tetra (4-sulphophenyl)
porphine dodecahydrate i.v. When the time between 2
fractions of 67.5 Jcm-2 and 90Jcm-2 was increased to 2
and 4 days respectively the incidence of necrosis fell to that
expected after a single fraction. Blood flow in the tail skin 5
days after the second light fraction, as measured by the
clearance of an intradermally injected solution of 133xenon
in 0.9% saline, returned to control values when the time
between 2 fractions was 2 days, with 67.5Jcm-2 fractions
and 3 days with 90JCm-2 fractions.
The time course of recovery of normal mouse tail skin
from photodynamic therapy as shown by these split dose
experiments was found to be similar to the time course for
the recovery of blood flow following a single light treatment.
Treatment with multiple fractions of 67.5Jcm-2 at inter-
vals of 4 days allowed a dose of 270Jcm-2 to be given
without producing necrosis although this is the ED50 dose
when given as a single fraction.
31P magnetic resonance spectroscopy in monitoring the
effects of photon and neutron irradiation on HT29 human
adenocarcinoma cells in vitro
S. Myint', H.M. Warenius', J. West-Jordan2, R. White',
R. Abraham2 & R.H.T. Edwards3
'Department of Radiation Oncology, 2School of Chemistry
and 3Department of Medicine, University of Liverpool,
Liverpool, Merseyside, UK.
The application of 31P NMR to the study of living cells has
provided a non-invasive monitoring of cell energetics and
offers a method for observing the effects of radiation on
metabolism of tumours.
31P NMR can be used to determine the relative concen-
tration of ATP, creatinine phosphate (PCr), inorganic phos-
phate (Pi) and several other phosphorated compounds such
as (PME, PDE, DPDE). In addition, tissue pH can be
calculated from Pi chemical shift.
We have used 31P NMR to study the metabolic changes
related to hypoxia and have characterised the spectral
changes occurring during recovery from hypoxia. There was
a fall in ATP levels with concomitant increase in inorganic
phosphate levels during hypoxia and these changes are
almost completely reversed during recovery from hypoxia.
Following irradiation with photons and neutrons, the
pattern of recovery from hypoxia differs. The irradiated
HT29 cells showed an increase in Pi/ATP, PM/ATP and also
the value of Pi, with maximum effect occurring after 3h.
These changes are more marked following neutron irradia-
tion and the increased Pi/ATP ratio persists after recovery.
The significance of these findings requires further investi-
gation. It is of interest, however, that 31P NMR enables
effects of protons and neutrons to be evaluated in intact
living cells in non-DNA sites.
Non-invasive ablation of liver tumours using focussed
ultrasound
G. ter Haar', D. Sinnett2 & J. Dodds3
'Department of Physics, 2Department of Surgery, 3Haddow
Laboratories, Sutton and Institute of Cancer Research,
Sutton, UK.
Ultrasonic energy may be focussed in such a way that it can
be concentrated within a small volume of tissue. If suffi-
ciently high power levels are used, tissue lying within the
focal region may be selectively destroyed at depth, leaving
surrounding tissue undamaged. The primary mechanism for
damage is heating, temperatures in the region of 80°C being
achieved within 10-15 sec. The region of damaged tissue can
be visualized on a diagnostic ultrasound image, as it is
created. This technique potentially provides a method for the
non-invasive treatment of liver metastases, without damage
to intervening tissues, while allowing 'real-time' monitoring
of the extent of tissue damage.
The effect of focussed ultrasound lesions on normal rat
liver has been investigated, and the capacity of the liver to
accommodate and replace the damaged volume has been
studied. After 10 weeks there is no sign of the ultrasonically
produced lesion.
Louise Buchanan Memorial Lecture
The biology of melanoma: Implications for early detection
R.M. MacKie
Department of Dermatology, University of Glasgow,
Glasgow, UK.
The incidence of cutaneous malignant melanoma is currently
rising rapidly and a high proportion of affected individuals
are otherwise healthy young adults. Although both the
World Health Organisation and the European Organisation
for Research and Treatment of Cancer run trials on mela-
noma chemotherapy, there is no proven effective adjuvant or
therapeutic regime yet available.
It is possible to prognosticate with remarkable accuracy
for melanoma patients at the time of presentation with their
primary tumour as five year survival is directly and inversely
related to the tumour thickness. It thus follows that encour-
aging early recognition and prompt surgical therapy is
currently likely to be the most effective method of reducing
or at least controlling mortality. Changing approaches to
surgical management will also be discussed.
Proffered papers
New Approaches to Diagnosis and Treatment
Use of interleukin 2 in human cancer: In vitro and in vivo
studies and potential for augmentation with monoclonal
antibodies
A.C. Dalgleishl, M. Malkovskyl, C. Bello2 & P. Sondel2
'MRC Clinical Research Centre, Harrow, Middlesex, UK;
and 2University of Wisconsin, Madison, USA.
Previous results have shown that human peripheral blood
leukocytes (PBL) expanded in interleukin 2 (IL-2): i.e.,
lymphokine activated killer (LAK) cells, can destroy various
normal and tumour target cells. The induction of this non-
specific cytotoxic activity is independent of de novo DNA
synthesis and cannot be further potentiated by gamma
interferon. We tested for the presence in clinical patients, for
LAK activity before and after IL-2 therapy. We also looked
for potential inhibition and augmentation of LAK with
monoclonal antibodies (MAb) in vitro.
We tested the effect of monoclonal antibodies to LFA-1,
CD2, CD3, CD4, CD8 and HLA molecules on killing
mediated by LAK cells on peripheral blood lymphocytes,
K562 and Daudi cells. LAK activity from clinical patients
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Anti-LFA-l strongly inhibited the killing of normal PBL
and to a lesser extent the killing of tumour cells. Anti-CD2,
CD4, CD8 and HLA class I did not inhibit non-specific
killing. In contrast, anti-CD3 potentiated the killing of
peripheral blood lymphocytes, K562 and Daudi cells.
Regional perfusion of antibody/isotope conjugate can increase
tumour uptake
T. Hennigan, R. Carpenter, J. Matthews, A. Chidlow,
B. Pedley, R. Begent & T. Allen-Mersh
Departments of Surgery and Medical Oncology, Charing
Cross and Westminster Medical School, London, UK.
The value of antibody/isotope conjugate (AIC) in delivering
a lethal radiation dose to solid tumours is limited by poor
differential uptake of tumour when compared to normal
tissue. We have assessed whether regional perfusion of AIC
increases tumour uptake in a novel animal model.
LS174T CEA-producing colon cancer cells were injected
subcutaneously to produce thigh tumours in nude rats. Three
weeks after inoculation, once solid tumours (mean weight
4.6g) were evident, the femoral artery was cannulated and
anti-CEA monoclonal antibody labelled with 70100,ICi 1311
was infused over 1.5h. The femoral artery was ligated at
completion of perfusion. In further animals, the femoral
artery was ligated but AIC was administered intravenously
into the tail vein. Animals were sacrificed at 48h and the
tumours were removed and counted.
After correction for difference in antibody dose, mean
uptake of regionally administered AIC (8.8 x 10-2jCi g -
tumour) was significantly greater than that of systemically
administered AIC (5.9 x 10-2pCig-1 tumour, Mann Whit-
ney test, P<0.05). Both systemic and regionally perfused
tumours showed significantly higher uptake than normal
liver, mean 3.7 x 10-2 /uCig-1 liver (Mann Whitney test,
P<0.04 and P<0.02 respectively).
Tumour uptake of AIC appears to be enhanced by
regional administration which might be of use in the
management of metastatic colorectal cancer.
Limitations of antibody targeting: A model showing higher
uptake ratios using a smaller, protein-bound molecule -
Application to MIBG
G.D. Thomas, A.R. Bradwell, M. Chappell, P.W. Dykes,
K. Godfrey & J.R.M. Ellis
University of Birmingham, Birmingham, U.K.
Poor tumour uptake of radiolabelled antibodies has pre-
vented their widespread application in diagnosis or therapy.
We have constructed a compartmental model to assess the
relative importance of the major limiting factors, namely: (1)
molecular size; (2) affinity of tumour binding and (3) binding
to normal tissue. The model also assesses the feasibility of
using a smaller molecule with a carrier protein delivery
system to prevent urinary loss. Amounts bound and free in
plasma and ECF as well as on tumour and normal tissue
receptors are calculated over time following injection. Differ-
ential rate equations with widely varying rate constants are
solved using FACSIMILE which avoids the inaccuracy of
steady-state assumptions previously necessary in such
models. It is also possible to simulate clearance of protein-
bound molecules from the system (by injecting a competitor
for the protein binding site) when tumour counts have
reached a maximum. Uptake ratios of over 100 can result.
Support for the binding-protein concept comes from studies
of MIBG which has small dimensions and achieves high
tumour concentrations. We have shown that it is bound to
plasma proteins in vitro and suggest the possibility of
improving uptake ratios based on this model.
CEA expression and radioimmunodetection of pancreatic
tumours and cholangiocarcinoma
A. Jewkes, F. Macdonald, W.H. Allum & R. Downing
Surgical Immunology Unit and Department of Surgery,
University of Birmingham and Queen Elizabeth Hospital,
Birmingham, U.K.
Radioimmunodetection using antibodies to carcinoembryonic
antigen (CEA) is effective in localising gastrointestinal
adenocarcinoma. Its usefulness may be of limited value
unless the information gained is unobtainable by other less
labour intensive diagnostic procedures. Pancreatic carcinoma
and cholangiocarcinoma are both difficult to differentiate
from their non-neoplastic counterparts, chronic pancreatitis
and sclerosising cholangitis, using existing diagnostic
methods. Antigen expression of both these tumours was
studied using an immunohistochemical technique with a
monoclonal antibody to CEA. Seventy-seven percent of
pancreatic cancers were positive, as were 80% of cholangio-
carcinomas. Expression of CEA was markedly reduced in
terms of both intensity of staining and the number of
positive cells, in cases of chronic pancreatitis and sclerosing
cholangitis.
Patients with one of these conditions proven histologically,
were given 200,ug monoclonal anti-CEA antibody labelled
with iodine 131. Subjects are imaged at 24 and 48h and
results compared with laparotomy findings and/or CT scan-
ning. All 10 pancreatic tumours were clearly imaged using
this technique as were all bile duct tumours. There was
however significant uptake of antibody in many cases of
chronic pancreatitis and some cases of sclerosing cholangitis.
Despite the encouraging results of immunohistochemistry
studies these antibodies are unlikely to be able to differen-
tiate between benign and malignant pancreatic or biliary
conditions. The results suggest, however, that antibody tar-
getted therapy may be possible in these conditions.
Long acting somatostatin analogue in malignant carcinoid
syndrome
M. Ellis1, S. Levi3, E. Leung2, E. Adam2, J. Calam3 &
H.J.F. Hodgson
Departments of 1Oncology, 2Radiology and 3Medicine,
RPMS, Hammersmith Hospital, London, UK.
Long acting somatostatin has been advocated as treatment
for carcinoid syndrome. We report results in 10 patients with
gastrointestinal carcinoid with hepatic metastases, resistant
to conventional blocking drugs, treated with long acting
somatostatin (sandostatin) in doses of 50 to 250pg tds by
self-administered subcutaneoius injection. In all patients
there was effective and rapid sympton relief, of diarrhoea,
flushing, palpitations, and wheezing when present. The effect
of therapy on release of serotonin from tumour was unpre-
dictable, both increased and decreased 5HIAA levels being
found, suggesting that much of the action of somatostatin is
peripheral. Serial observations of tumour size in this group
of patients did not show convincing evidence of a direct anti-
tumour action, with growth in tumour deposits over six
months of. therapy being recorded on sequential CT scans, or
obvious development of extrahepatic tumour masses occur-
ring. Side effects were limited to occasional local pain at the
injection site, and biochemical evidence of glucose intoler-
ance. Currently long acting somatostatin is an effective
means of preventing symptoms in carcinoid syndrome, but
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Interstitial photodynamic therapy in man
D. Gibson', D.V. Ash1, J.W. Feather2, I. Driver2, P. King2
& S.B. Brown3
'Departments of Radiotherapy, 2Medical Physics and
3Biochemistry, University of Leeds, Leeds, UK.
A main limitation of photodynamic therapy (PDT) in treat-
ment of cancer is the limited penetration of light in tissue.
One possible way of increasing the range of tumours which
can be treated is to use optical fibres inserted into the
tumour to deliver light interstitially.
Four patients with 23 sites of superficial recurrent tumour
have been treated with photofrin II (1.5mgkg-1 i.v.) and,
72h later, interstitial irradiation, using a 200,um optical fibre
to deliver 50-300J of 630nm light from a copper vapour/dye
Posters
Tumour and Normal Tissue Biology
Lethal mutations and their effect on the application of
radjobiological results to radiotherapy
C.B. Seymour1 & C. Mothersill1' 2
'Saint Luke's Hospital and 2Dublin Institute of Technology,
Dublin, Ireland.
Much of the theory on which radiotherapy is based comes
from radiobiological studies of cells in culture, using the
Puck & Marcus clonogenic assay. However, by determining
the clonogenic survival of cells within survivor clones, we
have shown that there is a dose-dependent reduction in the
survival of these cells. When data obtained from conven-
tional Puck & Marcus clonogenic assays are corrected for
these residual cell deaths, which we have termed lethal
mutations, the shoulder to the survival curve is lost. This
association between the occurrence of a shouldered survival
curve and existence within the cell population of lethally
mutated or 'doomed' fraction was confirmed by examining
repair deficient cells which normally exhibit no shoulder and
by exposing cells to neutron irradiation, after which again no
shoulder is usually observed. In neither case were lethal
mutations evident.
Of major interest in radiotherapy are the results following
split dose irradiation since most patients are treated using
fractionated regimes. However, these suggest that, while the
single dose survival curve shoulder is eliminated, the split
dose shoulder remains. This finding is confirmed by the
construction of Elkind recovery curves which show that
'early' recovery taking place 0-2h post-irradiation mainly
results in cells which die later (lethally mutated cells), while
recovery taking place over 2-24h results in cells which
survive in the long term. The results have important impli-
cations for the construction of models relevant to radio-
therapy treatment planning and may also help to explain late
effects.
In vitro cell response measured in a dye exclusion and MTT
assay
J. Hanson', J.L. Moore1, D.P. Bentley2 & A. Bean'
'Department of Radiation Sciences, Velindre Hospital,
Whitechurch, Cardiff; and 2Department of Haematology,
Llandough Hospital, Cardiff, UK.
A dye exclusion assay based on the ability of fixed 'live' cells
to exclude alcian blue (Yip & Auersperg, In vitro, 7, 323
(1972)) has been evaluated as an assay to measure cell
laser. Also, 3 of the patients had a total of 6 lesions treated
with 50-75Jcm-2 of superficial light. All except two of the
sites treated with interstitial PDT showed partial tumour
regression and none of the sites developed skin necrosis.
Three sites treated with superficial PDT showed complete
tumour regression, and 3 sites showed partial regression.
Skin necrosis occurred at all 3 sites showing a complete
tumour response.
Our previous studies of superficial PDT showed a com-
plete tumour response rate of 83%, with 1.5 or 2.0mgkg-1
of photofrin II and 50-75Jcm-2 of light, which was closely
paralleled by skin necrosis. Comparing these results with the
new data presented suggests that interstitial PDT, as given in
this study, is less effective than superficial PDT. This may be
due to insufficient doses of light or alteration in light
absorption in tumour when light is applied interstitially.
These factors require further investigation.
response following chemotherapy. Initially cell lines (Molt 4
and Daudi) were used. After exposure, cells were cultured
for 4 days before fixation. After staining with alcian blue
(including duck RBCs as standard), cytospin slide prep-
arations were made and finally counter-stained with Giemsa.
Dose response data was obtained following radiation or drug
exposure. To determine the application of this assay we have
also now assayed 13 samples from 7 patients with CLL and
have obtained dose responses in most cases when tested
against chlorambucil and novantrone. The CLL samples
were also assessed in the MTT assay (Twentyman &
Luscombe, Br. J. Cancer, 56, 279 (1987)). This assay is based
on the metabolism by viable cells of a tetrazolium salt
producing formazan crystals which are solubilised and the
resultant absorbance measured. Of the CLL samples, 9 of 13
gave significant formazan production where dose responses
were detectable. Our results suggest these assays may have
clinical use and we are currently undertaking a larger study
of CLL patients.
Radiosensitive human tumour cells are not recovery deficient
J.H. Peacock, A.M. Cassoni, T.J. McMillan & G.G. Steel
The Institute of Cancer Research, Sutton, Surrey, UK.
Cellular recovery from radiation damage has often been
demonstrated using the split-dose experiment and the results
interpreted using the multi-target model of radiation effect.
This model predicts that once the fraction dose used in a
split-dose experiment is off the shoulder of the survival
curve, then recovery will remain constant. In contrast the
more widely used linear-quadratic model (LQ) predicts that
recovery will increase steeply as an exponential function of
dose squared, at a rate determined by the B-component of
the LQ equation.
To test these predictions we have performed split-dose
experiments on four human tumour lines of widely differing
radiosensitivity. The pattern of the results follows that
predicted by the LQ model suggesting that the B-component
of that model may be used as a measure of cellular recovery.
The most surprising result, however, is that our data
shows that recovery capacity increases with increasing radio-
sensitivity. This is opposite of what is expected since it is
usually accepted that cellular radioresistance is at least partly
due to increased cellular recovery capacity. In addition, the
data throw doubt on the common assumption that cells
which have very steep radiation survival curves are recovery
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Cellular recovery in sensitive and resistant lines of the
L1578Y murine lymphoma
T.J. McMillan, J.J. Eady, J.H. Peacock & G.G. Steel
Radiotherapy Research Unit, The Institute of Cancer
Research, Sutton, Surrey, UK.
Lines of the L5178Y lymphoma which vary widely in their
sensitivity to ionizing radiation have been used in the past to
examine the molecular basis of radiosensitivity. Two such
lines, LY-S and LY-R which differ in their sensitivity by a
factor of 5, have been investigated here to establish their
recovery proficiency and thus assess their suitability for
studies of DNA repair. Two commonly used assays of
recovery capacity have been used. The extent of dose-rate
sparing is measured by comparing the survival of cells after
acute and low dose rates. Split dose experiments assay the
recovery of the cells when two halves of an acute dose are
separated in time.
Both LY-R and LY-S show a decrease in sensitivity as the
dose rate is decreased but the extent of this suggests that
there is little difference in the recovery proficiency of the two
lines. In contrast the recovery ratio (RR) in split dose
experiments at 0.01 survival suggest that the more resistant
line (LY-R) has a recovery capacity which is twice that of
the sensitive line (LY-S).
This inconsistency is due to the underlying assumption of
a multitarget model in using only one level of cell kill in split
dose experiments. As an alternative the linear-quadratic (L-
Q) model infers that RR will be a variable for each cell line
which depends on the dose and on the B coefficient. This B
value may thus be a better measure of recovery capacity and
if used for these lines we conclude that LY-S is in fact more
recovery proficient than LY-R. These results emphasize the
difficulties involved in measuring recovery in cells and
suggest that recovery proficiency need not decrease with
increased sensitivity.
Quantification of CEA synthesis and secretion by different
cultured human tumour cell-lines
J.R.M. Ellis, A.R. Bradwell, P.W. Dykes & G.D. Thomas
Immuno Diagnostic Research Laboratory, The Medical
School, University of Birmingham, Birmingham B15 2TJ,
UK.
Carcinoembryonic antigen (CEA) has been described as an
oncofetal protein, being expressed in greater concentrations
on embryonic and malignant tissues compared with normal
adult cells. Antibodies raised against this protein have been
applied to radioimmunodetection (RAID) studies in both
animals and humans, but with limited success to date.
Relative rates of CEA synthesis and secretion by normal and
malignant cells are of major importance and their accurate
measurement has not previously been possible. To achieve
this, CEA-secreting human tumour cell lines were cultured in
medium containing tritiated L-leucine to produce labelled
CEA which was then isolated from the cell supernatant by 2-D
immunoelectrophoresis and precipitated against anti-CEA. A
multi-wire proportional camera (MWPC) was then used to
quantitate the activity in the protein precipitate and from
this value the amount of CEA produced was calculated.
Preliminary results with three tumour cell lines show that
CEA levels of the order of 10-2 ng are detectable from
supernatants of 106 cells cultured for 72h. Future work will
enable calculation of CEA production for these cell lines and
eventually for malignant and normal tissues removed during
surgery and maintained in short term culture. Once CEA has
been assessed the technique could be applied to other
tumour associated proteins to evaluate their potential use for
RAID.
Flavone acetic acid (FAA) (LM975, NSC 347512) induces
rapid massive necrosis in a murine transplantable
adenocarcinoma (MAC 26)
C.V. Duke, J.A. Double & M.C. Bibby
Introduced by S.M. Crawford, Clinical Oncology Unit,
University of Bradford, Bradford, UK.
FAA is a novel anti-cancer agent undergoing clinical evalu-
ation in Europe and the USA. It is highly active against a
series of transplantable s.c. solid colon tumours in mice
(Bibby et al., Br. J. Cancer, 55, 159 (1987)). The response of
MAC 26 was particularly impressive as this tumour is refrac-
tory to standard cytotoxic therapy. Previous studies also
indicated that these responses did not correlate with direct
cell kill as demonstrated by in vitro cytotoxicity and that the
establishment of a vasculature appeared to be important.
In an attempt to elucidate the mechanisms of action of
FAA we have followed histological changes and effects on
blood flow in the well differentiated slow growing cystic
adenocarcinoma MAC 26. Tumour blood volume was
measured using an Evan's blue perfusion technique (Harada
et al., J. Pharm. Pharmac., 23, 218 (1971)). A single i.p.
therapeutic dose (90% tumour volume inhibition) of FAA
(200mgkg-1) produced a 60% reduction in tumour blood
volume first demonstrated 4h after treatment and which
persists for at least 24h. Parallel histology studies demon-
strated massive tumour necrosis at 24h with necrotic
changes being seen as early as 2h after treatment. An
equivalent therapeutic dose of local irradiation does not
produce these histological effects.
These observations substantiate our earlier suggestions
that tumour vasculature may be involved in the dramatic
response of s.c. tumours to FAA. This may provide an
explanation for the lack of response seen in the clinic where
the biology of systemic disease may be very different from
that of subcutaneous tumours in mice.
Anti-tumour activity and bone marrow toxicity of novel
chloroethylnitrosoureas
A.M. Matthew', C.G.Boynton2, M.C. Bibby',
J.A. Double' & S.M. Crawford'
'Clinical Oncology Unit and 2School of Biomedical Sciences,
University of Bradford, Bradford, UK.
The development of analogues of chloroethylnitrosoureas
with reduced toxicity has been a major goal. Ehresmann et
al. (Arch. Pharm., 317, 481 (1984)) have synthesized a series
of compounds with the chloroethylnitrosocarbamoyl (CNC)
residue linked to an amino acid or its derivative. CNC-
alanylalanine (E94) and CNC-glycinemethylamide (El 26)
were examined, using the clinically active, taurine based
nitrosourea (TCNU) as a positive control. Anti-tumour
activity was assessed against three lines of differing growth
characteristics and morphology from the mouse adeno-
carcinoma of the colon (MAC) series. At equivalent CNC
concentrations (0.1 mM kg-1) TCNU and E126 produced
over 90% tumour weight inhibition of MAC 13 and 80%
tumour volume inhibition of the relatively insensitive solid
tumour, MAC 26. E94 was inactive against MAC 26 despite
a higher level of CNC (0.17mMkg-1'), but exhibited
improved activity against the ascitic tumour, MAC 15A, with
a four-fold increase in median survival time and two cures.
Marrow toxicity was assessed by a spleen colony forming
unit assay at anti-neoplastic dose levels. TCNU and E126
showed marked marrow toxicity with no detectable surface
colonies while E94 showed no significant myelosuppression
with a survival fraction of 0.98; marrow toxicity was only
demonstrated at levels in excess of the maximum tolerated
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carrier groups in determining the activity and toxicity of the
chloroethylnitrosoureas. The demonstration of anti-tumour
activity at non-myelosuppressive dose levels with CNC-
alanylalanine is encouraging for the development of nitroso-
ureas with improved therapeutic indices.
Differential sensitivity of malignant cells to saturated
18-carbon fatty acids in vitro
B. Fermor', N.A. Habib', J.R.W. Masters2, J. Miller',
C.B. Wood3 & R.C.N. Williamson3
'Department of Surgery, Bristol Royal Infirmary; 2Institute
of Urology, London; and 3Department of Surgery, Royal
Postgraduate Medical School, London, UK.
The membranes of malignant cells showed increased oleic
acid in relation to stearic acid content in comparison with
their normal counterparts (Wood et al., Eur. J. Oncol., 11,
347 (1985)). Saturated stearic and its derivative dihydroxy-
stearic (DHSA), and monounsaturated oleic acids were
tested for their ability to inhibit colony formation of 5
malignant cell lines, I normal urothelium and I normal
fibroblasts in vitro. Stearic acid was up to 5 times more
cytotoxic than oleic acid. Four out of five tumour cell lines
were more sensitive to stearic acid than the normal fibro-
blasts (<0.001 <P<0.05). The three tumour cell lines tested
showed statistically significant (<0.001<P<0.006) differen-




Colon tumour HT29 22.44+ 1.2
Bladder tumour RT1 12 11.20+1.2
Testicular tumour 833K 22.24+0.4
Normal urothelium HU609 34.10+0.5
Normal fibroblasts HFL 36.31 +1.1
Our data suggest saturated 18 carbon fatty acids to be
more cytotoxic to tumour cells than monounsaturated 18
carbon fatty acids and that this may be related to the higher
proportion of oleic acid in the tumour cell membranes.
Reactions of carboplatin with chloride ions - pharmaceutical
and clinical implications
M. Allsopp, G.J. Sewell, M. Northcott & C.G. Rowland
Postgraduate Medical School, University of Exeter, Exeter,
UK.
Phase I/II studies on the continuous infusion of carboplatin
with synchronous radiotherapy against solid tumours are in
progress at Exeter. For biological activity, carboplatin reacts
non-enzymically with water. We have shown carboplatin to
also undergo nucleophilic substitution with Cl- ions. These
reactions are important in continuous (5 day) infusions since
long-term drug stability is essential, particularly in infusions
containing carboplatin and Cl- ions, the latter arising as a
formulation excipient or drug counter-ion in multiple agent
regimes. The plasma Cl- concentration is 0.1 M so the
reaction is also significant in vivo. Kinetic studies on carbo-
platin degradation were carried out at elevated temperatures
in the presence of 0, 0.1, 0.25 and 0.4 M M Cl-.
Degradation was 1st order and the observed rate constant
(Kobs) comprised two components (Kobs =K, + K2 [Cl-]),
where K1 and K2 are hydrolytic and [Cl-] dependent rate
constants respectively. Values of K, and K2 were determined
at pharmaceutically and clinically relevant temperatures and
from these the times for 5% (Tg9) and 50% (TD) degrada-
tion were calculated. At 25°C values of 9.74 x 10 -4 and
3.14x10-3[Clj].h-1 were obtained for K, and K2 respec-
tively, giving T95 values for carboplatin of 52.7h in water
and 29.2h in 0.9% saline. Carboplatin should not be
reconstituted with saline for continuous infusion. At 37°C
with 0.1 M Cl- the carboplatin Tj was 334h and 5 putative
plasma intermediates with possible biological/
radiosensitisation activity are proposed. The in vitro plasma
T! was approx. 30h suggesting that carboplatin reacts with
other plasma components in addition to Cl- ions.
Technetium-99m HMPAO SPECT and blood flow patterns
in human lung tumours
N.P. Rowell, V.R. McCready, D. Tait, M.A. Flower,
B. Cronin & A. Horwich
MRC Radiobiology Unit, Harwell, and Radiotherapy Unit,
The Royal Marsden Hospital, Sutton, Surrey, UK.
In order to assess the blood flow patterns through human
lung tumours, 20 patients received 400-750 MBq 99mTc-
HMPAO intravenously 10min prior to single photon emis-
sion computed tomography (SPECT). Ratios of uptake in
the whole tumour relative to normal lung ranged from 0.35
to 1.53 (mean 1.01) with 8 tumours showing less uptake than
normal lung and 10 showing greater uptake. In one patient
the tumour was not distinguishable from surrounding lung
and in another a large pleural effusion prevented evaluation.
Tumour: lung ratios for central tumour regions ranged from
zero to 1.83 (mean 0.80) with 13 showing lower uptake than
normal lung and 5 showing greater uptake. Duplicate scans
were performed in 8 patients demonstrating satisfactory
reproducibility. This technique provides a simple and repro-
ducible method for the assessment of tumour blood flow
Development of a technique for optimising cancer therapy
using a human epithelial model system
C. Mothersill'2, C.B. Seymour', A. Cusack',
T.P. Hennessy3 & M. Moriarty'
'Saint Luke's Hospital, 2Dublin Institute of Technology and
3St. James's Hospital, Dublin, Eire.
The optimisation of cancer therapy regimes is mainly done
by retrospective analyses of clinical trial results. The idea of
experimentally optimising treatments prior to use on particu-
lar tumours or patients is not new but experimental models
are largely irrelevant or too difficult to be used widely.
Our group has developed a quick, easy and widely applic-
able tissue culture model which is giving promising results in
this area. Explants from a wide variety of normal human
tissues (genitourinary, gastrointestinal tract, glandular) and
their respective tumours give rise over four weeks to largely
epithelial outgrowths when cultured in a basal medium with
serum, hydrocortisone, insulin and specific hormone sup-
plements. The outgrowths can be treated with appropriate
combinations of radio- and/or chemotherapy at any time
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after explanation, using any sequence or dose required.
Results are analysed as reduction in growth area relative to
the untreated control. Growth is confirmed using autoradio-
graphy or Kl 67 antigen (Dako) and the epithelial nature of
the culture is confirmed using cytokeratin immunocyto-
chemistry.
Results using bleomycin+radiation on oesophageal normal
and tumour tissue or cisplatin+radiation on bladder normal
and tumour tissue suggest tumour cytocidal results may be
optimised by the concurrent application of a clinically
equivalent chemotherapy dose with a small single radiation
dose. This reduced tumour cell growth to zero over a four
week period after treatment, while sparing the surrounding
normal tissue. Higher drug or radiation doses produced
equal cytotoxicity in normal and tumour explants.
The technique has potential for predictive tumour therapy
and clinical trials are in the process of being set up.
New Approaches to Diagnosis and Treatment
majority needing palliation. Low power interstitial laser
hyperthermia offers a means of producing localised thermal
necrosis of predictable nature and extent in these tumours
without the need for resection, and which heals safely.
Light from a low power Nd-YAG laser is transmitted via
a 200m fibre which is inserted in the centre of the target
organ. With a single fibre, lesions up to 1.6cm (in rat liver)
and 1.6cm (in canine pancreas) in diameter can be produced
with 1 W for 670-1,000 sec which heal safely, although higher
powers (2W) can cause lethal pancreatitis. Using multiple (4)
fibres activated simultaneously (1.5W for 670sec per fibre)
in liver, larger lesions of overlapping areas of thermal
necrosis can be made, which measure 3.5 x 3 x 2.7cm and
heal by fibrosis and regeneration, but take 5-6 months to do
so. In the pancreas with multiple fibres (1 W per fibre for
1,000 sec) inflammatory areas 6 x 2cm can be produced that
heal by inflammation and fibrosis by 3 months. Hyper-
amylasaemia is seen, but little clinical pancreatitis. Ultra-
sound has been used to insert and place fibres and to
monitor accurately the evolution of the thermal damage.
Although not yet proven, it is likely that necrotic tumour
will heal in a similar manner to necrotic normal tissue in
these organs, so making this technique potentially valuable
for in situ necrosis of these difficult tumours, particularly as
it may be possible to match the extent of laser necrosis to
the extent of tumour spread with ultrasound control.
131I-MIBG targetted radiotherapy in Yorkshire
A.S. Bulman, R.E. Taylor, M. Sheppard & I. Lewis
Departments of Radiotherapy, Medical Physics and
Paediatric Oncology, Cookridge Hospital, Leeds, UK.
Meta-iodobenzylguanidine (MIBG) is a synthetic molecule
taken up by adrenergic neuro transmitter vesicles. Labelled
with 13lIodine in 18.5 MBq doses it is used for scintigraphic
imaging of neurectodermal tissues and tumours. We report 4
cases in whom therapeutic doses were used as 'targeted
radiotherapy'.
Patient 1, aged 11, had metastatic nodal neuroblastoma 4
years after primary treatment. Two patients had neuro-
blastoma persisting despite conventional treatment (patient
2, aged 4, in marrow, and patient 3, aged 5, in primary
abdominal site and bone). Patient 4, aged 15, had inoperable
right adrenal paraganglioma with hypertension.
After thyroid blockade 74 MBq tracer doses were used to
estimate therapeutic doses, which were given as 45min i.v.
infusions of 3.7, 3.3, 2.8 and 5.6 GBq respectively, requiring
admission to a designated side ward for radiation protection
purposes for one week. Whole body scan and static scinti-
grams were obtained from days 3-7 and weekly for four
weeks enabling whole body and region of interest clearance
curves to be plotted. Nausea was seen in patients 3 and 4
whose primary sites were adjacent to liver, but no major
treatment related side effects were seen. Patient I showed
tumour size reduction of more than 50% for five weeks, 2
and 4 showed no response, 3 advancing disease.
Work is continuing on the biological behaviour of 1311_
MIBG in children to allow increased tumour doses to be
given without excessive whole body dose. A UKCCSG Study
is now open for children with advanced neuroblastoma.
Interstitial laser hyperthermia: A potential new treatment for
tumours of the liver and pancreas
A.C. Steger1, S.G. Brown', W.R. Lees2 & the late C.G. Clark
Departments of 1Surgery and 2Radiology, University College
and Middlesex Hospital, London, UK.
Few cancers of the liver and pancreas are suitable for either
curative resection or radiotherapy or chemotherapy, the
Breast Cancer
4-hydroxyandrostenedione (4-OHA) as second line hormonal
therapy in advanced breast cancer
P.A. Murray, L. Perry, J. Gilmore & P.N. Plowman
St. Bartholomew's Hospital, London, UK.
The major source of oestrogen production in postmeno-
pausal women is by the aromatisation of circulating
androgens in extra-adrenal sites. The aromatase inhibitor
aminoglutethimide has a 25% response rate as second line
hormonal therapy in advanced breast cancer but its useful-
ness is limited by toxicity, particularly in the elderly (Hum.
Toxicol., 6, 227 (1987)).
4-OHA is a more potent specific aromatase inhibitor
which has been shown to be active in breast cancer although
the optimum dose is unknown (Cancer Res., 47, 1957
(1978)). Thirteen postmenopausal patients failing other hor-
monal therapy for advanced breast cancer have been treated
with 4-OHA 250mg i.m. fortnightly.
The mean serum oestradiol (±s.e.) (pmolP1) measured by
radioimmunoassay prior to treatment and at weeks 1, 2 and
8 was 30.0+5.7, 12.8+2.4, 12.9+2.2 and 15.9+2.6,
respectively.
Clinical response has been observed in 3 patients (PR)
with disease stabilisation in 1. Progression has occurred in 6
patients and 3 are not yet assessable. Therapy has been well
tolerated and apart from transient pain at the injection site
there have been no significant side effects. 4-OHA 250mg
fortnightly produces a significant reduction in serum oestra-
diol levels in postmenopausal patients and the clinical
response to date is encouraging. Its lack of systemic toxicity
is an advantage over other second line endocrine therapy.THIRD MEETING OF THE BRITISH ONCOLOGICAL ASSOCIATION 535
Long term cosmesis and morbidity following lumpectomy and
radical radiotherapy for breast cancer
A.M. Brunt, A. Drury, H. Ellis, A.G. Goodman &
R.H. Phillips
Westminster Hospital, London, UK.
Eighty-one consecutive patients referred by one surgeon
(HE) following lumpectomy for breast cancer, and whom
received post-operative radiotherapy under the care of one
radiotherapist (RHP), were considered for cosmetic result
and morbidity assessment. All patients received 4,840cGy in
22 fractions to the breast and axilla, 5,940cGy in 27
fractions to the supraclavicular nodes and a 2,000cGy boost
to the primary site. Cosmetic results were quantified on a
four-point scale for telangiectasia matchline effect, fibrosis
and the doctor and patient's overall assessment. The surgical
scar was also examined and the morbidity was assessed by
shoulder abduction, upper and lower arm mid-point circum-
ference, and by pain in the breast, axilla and arm.
Forty-eight patients were assessed at a mean of 67.4
months from completion of radiotherapy (range 54-98
months), whilst 33 were non-assessable due to death, local
recurrence or were lost to follow-up. Telangiectasia and
fibrosis were slight or absent in 45 and 36 respectively and
moderate in the remainder. A matchline effect was not
observed in any patient. The surgical scar was not apparent
in 11, apparent in 35 and there was major tissue loss in 2. In
no case was there considered to be a serious distortion of the
breast. There was no significant difference in the range of
shoulder abduction or arm circumference between the treated
and untreated sides. One patient reported severe pain in the
arm, none did for the breast and axilla. We conclude that
the long-term cosmetic appearance and morbidity suffered
following lumpectomy and radical radiotherapy is highly
satisfactory.
Does flow cytometry accurately determine ploidy in ductal
carcinoma in situ of the female breast?
R. Carpenter, T. Cooke, J. Matthews, C. Dowle, K. Burn,
A. Locker & R. Blamey
Charing Cross and Westminster Medical School, Royal
Liverpool Hospital and Nottingham City Hospital, UK.
Flow cytometry is a convenient way of assessing tumour
ploidy, but recent studies using this technique have cast
doubt on earlier reports that ploidy determined by static
cytometry is related to prognosis in breast cancer. To assess
possible insensitivity of the automated method, we checked
results of flow cytometry by simultaneous static cytometry in
patients with pre-invasive breast cancer. Cell suspensions
obtained by enzymatic disaggregation of 65 in situ carci-
nomas of the breast from the Nottingham breast clinic were
stained by the Schiff reagent or diaminodio-2-phenylindol-
dichloride (DAPI) and DNA content measured by micro-




Flow cytometry Aneuploid 31 31
Diploid 16 18 34
Total 47 18 65
Thirty-one lesions reported aneuploid on flow cytometry
were confirmed by static cytometry, however, 16 of 34
identified as diploid were aneuploid on microdensitometry.
Flow cytometry over diagnosed diploidy in 47% of lesions.
Flow cytometry is less sensitive than static cytometry in
ploidy determination, which could explain discrepancies
between the published studies. To correct this problem when
diploidy is identified by flow cytometry, microdensitometry
should subsequently be performed.
An approach to the early identification of response to
tamoxifen in advanced breast cancer
R. Carpenter, A. Samuels, J. Matthews, S. Shousha,
J.I. Burn, D. Wright & J. Powell
Department of Surgery, Charing Cross and Westminster
Medical School, London, UK.
Breast cancer response to tamoxifen cannot be predicted
reliably from oestrogen receptor status. Activity of tumour a-
glycerol phosphate-dehydrogenase has been reported to
increase following tamoxifen. We investigated the effect of
tamoxifen on activity of this and other enzymes involved in
lipid biosynthesis: ca-glyceraldehydephosphatase-dehydro-
genase and malic enzyme. Changes in cellular DNA content
and thymidine kinase, an enzyme of DNA synthesis under
oestrogen control, were also monitored.
Needle biopsies of primary breast cancer were assessed for
histology, ploidy and enzyme activity before and 6 weeks
after commencing tamoxifen. Tumour response was assessed
by UICC criteria.
There was a significant reduction in thymidine kinase
activity from 5.87+0.95 to 1.98+0.41 Umg-i protein
(P<0.001, paired t) in 10 patients whose disease did not
progress over a mean of 4.6 months. In contrast, activity
increased from 3.43+1.43 to 3.95 + 1.52Umg protein in 5
patients whose disease progressed (x2, P<0.02). Neither
treatment or tumour progression were related to changes in
the other enzymes studied nor was response related to
aneuploid (n = 14) or diploid (n = 1) DNA content.
Tamoxifen response was not related to activity of the
enzymes of lipid metabolism tested in this study, however,
oestrogen sensitive aspects of DNA synthesis, of which
thymidine kinase is an example, appear more rewarding.
Prospective evaluation of a low maintenance care policy for
vascular access ('Hickman') catheters (VACs)
S.R. Ebbs, J.A. Saunders & M. Baum
Department of Surgery, King's College Hospital School of
Medicine, London, UK.
VACs are particularly suited to the administration of cyto-
toxics. As new low toxicity regimens allow home infusion of
chemotherapy, we have prospectively evaluated low inter-
vention catheter care ideally suited to this environment with
great financial and patient comfort benefits.
Fifty-two women with advanced breast cancer were ran-
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bolus injection through a peripheral vein or as a 24hr
infusion using a lightweight disposable pump (travenol in-
fusor) through a single lumen VAC. Twenty-six women had
VACs in situ for a total of 2,294 patient days (range 6 to 217
days. median 55 days). Two hundred and seventy-seven
infusors were administered over this period (range 0 to 25,
median 6).
No antibiotics, antiseptics, anticoagulants or occlusive
dressing were employed. The VAC was used for blood
sampling and the infusor connected. The patients returned to
their own home where the following day they disconnected
the infusor and 'recapped' the line, without flushing it.
Complications:








-infuse but not sample blood








Three exit site infections occurred in 2 women (11.5%); 1
patient developed inflammation around the subcutaneous
tunnel (4%); no patients suffered systemic infection. No
catheters became temporarily or permanently occluded
during 286 accesses.
There is no need for heparinisation and bacteriocidal
wound dressing for VACs.
Correlation between medroxyprogesterone acetate blood
levels and response in patients with breast cancer
A.D. Stockdale & A.Y. Rostom
Department of Radiotherapy and Oncology, St. Luke's
Hospital, Guildford, UK.
Thirty females with advanced or locally recurrent carcinoma
of the breast were randomly assigned to receive 1 g daily by
mouth, of medroxyprogesterone acetate (MPA) as either
provera, 100mgx 10, 200mgx5, (Upjohn) or farlutal
500mg x 2, (Farmitalia) tablets. MPA blood levels were
measured during day I and on days 7, 14, 21 and 28. Serum
cortisol levels are also available for the majority of patients.
One patient had a complete and 4 patients partial responses
to therapy (17%). Ten patients achieved stasis of previously
advancing disease (33%). Despite significant differences in
MPA concentrations between the 3 groups, objective res-
ponses and stasis were equally spread between preparations,
and showed no correlation with either MPA concentration
or suppression of serum cortisol. We find no evidence to
suggest that high doses of MPA produce greater responses
than achieved with low doses.
Pharmaceutical aspects of domiciliary continuous infusion
chemotherapy
G.J. Sewell, M. Allsopp, M. Northcott & C.G. Rowland
Postgraduate Medical School, University of Exeter, Exeter,
UK.
In the Home Oncology Programme, Exeter (HOPE),
antitumour agents are delivered as prolonged continuous
infusions over 5-14 days by ambulatory infusion pumps.
Pre-filled medication reservoirs are supplied to patients
during out-patient visits. The drug must remain stable during
refrigerated storage prior to use (up to 14 days) and also
during infusion where the infusion temperature in a holster-
worn ambulatory pump is 35-37°C.
We have determined the physical and chemical stability of
cytarabine, carboplatin, epirubicin, 5-fluorouracil and mito-
zantrone infusions during storage in - pump reservoirs and
during delivery from ambulatory pumps. Stability-indicating
HPLC methods were developed for this study. All five
infusions were physically and chemically stable under storage
conditions. There was no drug loss during infusion under in-
use conditions with the exception of carboplatin where 3%
of the drug degraded to cisplatinum. In further studies with
a-interferon-2b infusion (3mU), changes in the relative ratio
of interferon monomers occurred with the appearance of
degradation products under storage and in-use conditions.
This was attributed to monomer interconversion and
oligomer formation.
With the exception of ox-interferon, all of the infusions
were sufficiently stable for inclusion in the Home Infusion
Programme and have been in clinical use for at least 6
months.
Pharmacokinetic studies on mitozantrone in prolonged
continuous infusion regimes
M. Northcott, G. Sewell, M. Allsopp & C.G. Rowland
Postgraduate Medical School, University of Exeter, Exeter,
UK.
In a phase II study with 22 patients, advanced metastatic
breast cancer was treated with prolonged continuous infu-
sion of mitozantrone (2mgday-1 x 14 days). Although the
dosage regime of the continuous infusion was empirically
derived, response rates were encouraging (CR=26%,
PR=26% at 6 months).
We have carried out pharmacokinetic studies with some of
these patients and have compared pharmacokinetic para-
meters obtained in continuous infusion regimes with those
reported for traditional bolus or rapid infusion regimes.
Pharmacokinetic parameters will also be related to clinical
response/toxicity with the long-term objective of optimising
drug dosage in continuous infusion schedules. A solid-phase
extraction procedure and a sensitive HPLC assay were
developed and validated to determine mitozantrone in
plasma. The limit of detection was 500pgml-1.
The mean steady-state mitozantrone plasma level was
1.81 ngml-I (range 1.13-4.39, =6) and the mean area under
the curve (AUC) was 0.517,ug.hml-1 (range 0.35-
0.74yug.hml-1). This compares with peak plasma levels of
683 ngml - (Van Belle et al., Cancer Chemother. Pharmacol.,
18, 27 (1986)) and AUC values of 1.45pug.hml-1 (Ehninger
et al., Investigational New Drugs, 3, 109 (1985)) reported for
bolus regimes (14mgm 2 over 30min). Our results suggest
that peak-plasma levels are not essential for clinical response
and that availability of drug to the tissues (determined by
AUC values) are of a similar order in both regimes.
Enhancement by medroxyprogesterone acetate (MPA) of
cytotoxic effects of adriamycin (ADR) on breast cancer cells
N.A. Shaikh, A.M. Owen, M.W. Ghilchik & H. Brausberg
The Breast Clinic and Department of Chemical Pathology,
St. Mary's Hospital, London, UK.
Cyclical sequential hormonochemotherapy involving oestro-
gen, MPA and alternate use of two combinations of cyto-
toxic drugs has produced very promising responses in
patients with advanced breast cancer (Ghilchik et al., Br.
Med. J., 295, 1172 (1987)). In order to assess the positive
contributions of hormonal agents in this therapeutic schedule
we have examined the effects of MPA on the efficacy of
individual drugs using human breast cancer cells (MCF-70)
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in culture. Monolayers of cells were exposed to MPA or
control medium for 48 h followed by drug for 24h. The
washed cells were then allowed to proliferate with growth
medium for 3 days before being harvested and counted.
MPA significantly (P<0.025 or lower) enhanced the effect of
ADR (20nM) in 4 of 5 experiments. The effect was observed
at 10nM MPA and maximal at 40nM. Exposure to oestra-
diol (1 nM) for 24h prior to MPA treatment further
increased the action of MPA on the efficacy of ADR, while
oestradiol followed by control medium (48h) did not alter
the drug effect. A subline of MCF-7 cells unresponsive to
the growth inhibitory action of MPA responded to the
hormone with respect to enhancement of drug action. Simi-
lar effects of MPA have been observed with respect to the
actions of methotrexate and vincristine (Shaikh et al., Steroid
Biochem, 28 (Suppl.) 158S (1987)) and other drugs are under
investigation. The results support our clinical findings and
suggest that sequential hormonotherapy using MPA offers
an advance over other treatments and may benefit patients
even if their tumours have escaped or failed to respond to
growth inhibition by the hormone.
Development of a new transplantable hormone-responsive rat
mammary tumour model
S.A. Eccles, H.P. Purvies & M. Jarman
Institute of Cancer Research, Belmont, Surrey, UK.
The pre-clinical evaluation of new anti-oestrogen drugs
requires that their efficacy should be demonstrable in animal
tumour systems. Currently employed models include primary
chemically-induced (DMBA and MNU) rat tumours, and
human mammary tumour cell lines grown as xenografts in
nude mice. We set out to develop a transplantable hormone-
responsive tumour with reproducible growth and oestrogen
sensitivity in syngeneic rats.
From a tumour (induced by the s.c. implantation of an
oestrogen pellet) which initially was only transplantable in
oestrogen-supplemented female rats, we developed two cell
lines - OES HR 1 and 2 - which would grow in the absence
of additional oestrogen. Both tumours are hormone respon-
sive in that their growth is enhanced by oestrogen supple-
mentation and totally inhibited in males or ovariectomised
females. In addition, both tumour cell lines regress or show
stasis of growth in response to treatment in vivo with the
following 'anti-oestrogen' drugs: 4 hydroxy-androstene
dione, aminoglutethimide and tamoxifen. Under certain
dosage schedules tamoxifen was shown to be oestrogenic,
allowing an examination of this phenomenon in more detail.
These tumour lines will serve as a useful adjunct in the
screening of anti-endocrine agents. Also, since in the
presence of oestrogen they are capable of lymphatic and
haematogenous dissemination, we intend to investigate auto-
crine and paracrine influences in progression towards growth
factor independence and metastasis.
lodostearic acid inhibits mammary carcinogenesis induced by
nitrosomethylurea in rats
S.B. Kelly', N.A. Habib', C.B. Wood2, K. Apostolov2,
B. Baker2, M.J. Hershman2 & R.C.N. Williamson2
'Department of Surgery, Bristol Royal Infirmary, Bristol
and 2Department of Surgery, Royal Postgraduate Medical
School, London, UK.
Malignant transformation of the cell is accompanied by a
decrease in membrane rigidity, resulting in part from the
desaturation of stearic acid to oleic acid. The aim of this
study was to investigate the influence of stearic acid on
tumour development in vivo.
Nitrosomethylurea (NMU) rapidly induces mammary car-
cinomas in rats. Administration was by i.v. injection via the
tail vein at a dose of 5mg 00g-1 body weight. Two groups
of female Sprague-Dawley rats received either NMU (n =20)
or NMU plus iodostearic acid (n =23). Gas liquid chromato-
graphy was used to study changes in the fatty acid com-
position of rat erythrocyte membranes during mammary
carcinogenesis.
By week 16, 19 of 20 rats in the NMU group and 8 of 19
rats in the NMU plus iodostearic acid group developed
tumours. The mean number of tumours/rat was 3.8 in the
NMU group and 2.7 in the NMU plus iodostearic acid
group.
The mean saturation index (ratio of stearic acid to oleic
acid) of rat erythrocytes was 2.0+0.3 in rats receiving normal
saline and 1.09+0.28 in the NMU group (P<0.001).
These data indicate that iodostearic acid inhibits tumour
development in rats. In addition, the onset of tumours is
associated with a fall in the saturation index of rat
erythrocytes.
Gastro-intestinal Tract Malignancy
Comparison of prognosis of preoperative and operative.
perforation of the colon in colorectal cancer
M.P. Tilston & N.S. Ambrose & M.R.B. Keighley
General Hospital, Birmingham, UK.
During the 3 year period in which we have been running a
specific clinic for follow-up of colorectal cancers, 12 patients
have presented to our unit with intestinal obstruction and
signs of perforation (group 1). In this series we have
compared the clinical course of these patients with that of
patients who sustained inadvertent colonic perforation at
operation (group 2). Mean age and sex distribution was
similar in the 2 groups, as was Dukes' staging and degree of
differentiation. However, a single patient with carcinoid of
the appendix presented with peritonitis. Left sided tumours
predominated in both groups but rectal tumours, which
accounted for the vast majority of those undergoing opera-
tive injury (65%), were notably absent from those presenting
with peritonitis, presumably due to the capacious nature of
that portion of the bowel. Mean follow-up of group 1 was
27 months (1-124 months) and of group 2 was 56.5 months
(11 135 months). At the time of writing 11 from group 1 are
alive (92%), 7 of whom (58%) have no evidence of recur-
rence. In group 2, 14 (70%) are alive but only 8 are free of
disease. Only 1 patient in group I has died of metastatic
disease, whereas 6 patients (30%) in the latter group suc-
cumbed to carcinomatosis. The mean time to appearance or
detection of recurrent disease was 17.4 months in group I
and 27.1 months in group 2.
Does postoperative sepsis influence the prognosis of
colorectal cancer?
M.P. Tilston, C. Hall, N.S. Ambrose & M.R.B. Keighley
General Hospital, Birmingham, UK.
We have followed-up all colorectal cancers in a specific clinic
over the last three years, and during this period 24 patients
had postoperative intra-abdominal or intrapelvic sepsis (19
with clinically evident sepsis and 5 with radiological evidence
of anastomotic leakage). The subsequent clinical course of538 THIRD MEETING OF THE BRITISH ONCOLOGICAL ASSOCIATION
these patients is compared with that of an age/sex and stage
matched cohort (N=25), who did not have evidence of
postoperative sepsis. Mean age of group 1 was 65.2 years
and of group 2, 66.7 years. Left sided tumours predominate
in both groups, with a slightly higher proportion of right
sided tumours in group 2 than in group 1. Mean follow-up
of both groups exceeded 2 years (group 1: 149.5 months,
group 2: 38.4 months). Twenty-one patients in group 1 and
23 in group 2 are alive and available for follow-up, 2 cases
from each group having died from carcinomatosis and a
further 1 from group 1 having died from cardiovascular
disease. However, overall recurrence rates differ markedly. In
group 1, 5 patients have had evidence of local or distant
disease (21%), whereas 10 patients from group 2 (40%) are
affected. Although this does not achieve statistical signifi-
cance, there would appear to be an important trend towards
improved recurrence rate with postoperative sepsis. This
might conceivably arise from either a general non-specific
stimulus to the immune system, brought about by infection
or by the occurrence of an unfavourable environment for
implantation to take place.
Cancer in Crohn's disease after diversionary surgery: A
study of the crypt cell production rate
M.C. Winslet, D.J. Youngs, A. Allan & M.R.B. Keighley
General Hospital, Birmingham, UK.
given at 1 cm from the sources using the Selectron oesopha-
geal applicator. Twelve Cs 137 sources of initially 40mCi
strength are used and the treatment is delivered in approxi-
mately one and a half hours. Four patients have received
external beam doses of 50Gy in 4 weeks (daily fractiona-
tion). This is the department's standard radical treatment
and after this a further 1OGy is given at 1 cm using the
Selectron.
At 6 months the survival is 65%. A group of 16 patients
treated radically in the 3 years prior to introduction of the
Selectron treatments for carcinoma of the oesophagus had a
6 month survival of 50%
In view of the fact that the Selectron group included 3
patients with recurrent disease following either previous
surgery or radiotherapy and only 2 patients have not been
treated with the Selectron, due to poor general condition,
these preliminary results are very interesting.
The influence of dietary fat on the fatty acid profile of red
blood cells (RBC) and adipose tissue in patients with
colorectal cancer (CRC)
J.P. Neoptolemos, H. Clayton, M. Nicholson,
J. Ollerenshaw, B. Johnson, J. Mason, K. Manson, R. James
& P. Bell
Departments of Surgery, Medicine and Nutrition, University
of Leicester, Leicester, UK.
A high incidence of tumours has been reported (Greenstein A reduced ratio of RBC stearic to oleic acid ratio has been
et al., Am. J. Surg., 135, 86 (1978)) after diversionary proposed as a highly sensitive marker of CRC. However,
surgery for Crohn's disease which is related to the duration objections have been raised about matching of patients and
of Crohn's disease rather than that of the bypass. To assess the role of dietary fat has not been previously assessed.
whether this high incidence is due to changes in colonic Using gas liquid chromatography, the fatty acid profile in
cytokinetics after bypass, the rectal crypt cell production rate RBCs and adipose tissue was determined in 49 patients with
(CCPR) has been assessed in patients with defunctioned CRC and 49 age and sex matched controls. In the CRC
Crohn's colitis (DCC) (n=9) and a control group (DC) for a group there were marginally increased levels (mean s.e.m.) of
non-inflammatory condition (n=6). The mean duration of stearic acid (18.1 +0.4 vs. 17.2+0.3, P=0.06) and oleic acid
Crohn's disease was 58 (12-134) months. The mean diver- (20.3 +0.4 vs. 19.0+0.4; P=0.06) and decreased arachidonic
sionary period was 9 (2-16) months for Crohn's disease and acid (22.0+0.4 vs. 23.4+0.6, P=0.04). There was no dif-
3 (1-8) months for controls. Results were compared with ference in the RBC stearic to oleic acid ratio between the
controls (C:n=21) and patients with ileal Crohn's disease two groups (0.9+0.02 vs. 0.91+0.01); there was no correla-
(CD:n=9) and Crohn's proctitis (CP:n=15) who had not tion of this ratio with the Dukes' staging. The poly-
been defunctioned. unsaturated/saturated (P/S) ratio of dietary fats and adipose
tissue was correlated in both groups (P<0.001). The RBC P/
DCC DC C CD CP S ratio was also correlated with the dietary P/S ratio in the
CCPR+s.e.m. 2.5+0.4 2.9+0.6 3.2+0.5 4.0+0.7 2.8+0.7 cancer group (P<0.01).
(cellscrypt lh 1) In conclusion, small differences of RBC fatty acids in
CRC are linked to dietary fat. The RBC stearic to oleic acid
This study has failed to demonstrate anv chane in the was not diagnostic of CRC in this study
cellular proliferation rate in the excluded colon after a
disease duration of 5 years and a diversionary period of 9
months. It suggests that the risk of carcinogenesis in
bypassed bowel is not due to changes in cell kinetics.
Combined external beam and intracavitary radiotherapy for
carcinoma of the oesophagus
P.J.D.K. Dawes, M.B. Clague & E.M. Dean
Regional Radiotherapy Centre, Newcastle General Hospital,
Newcastle upon Tyne, UK.
Thirty patients have been treated with megavoltage external
beam radiotherapy and intraluminal radiotherapy using the
Selectron oesophageal applicator and external beam or 8 MV
photon therapy.
Twenty-six patients have received 30Gy in 10 daily frac-
tions through either 2 or 3 field plans. Either on the last day
of treatment or shortly afterwards a further 1OGy has been
Resection of the rectum for cancer in a district general
hospital
R.A. Cobb', H. Reece-Smith' & D.C. Britton2
1Battle Hospital, Reading and 2Royal United Hospital,
Bath, UK.
A retrospective study of all patients who had either an
anterior resection (AR), or an abdomino-perineal resection
(AP) for rectal cancer in Bath Health District in the 12 years
1967-1978 was undertaken with a minimum follow-up of 5
years.
There were 329 operations performed (AR: 91, AP: 238).
Serious complications were recorded in 22.2% of patients
(AR: 28.6%, AP: 19.7%). The operative mortality was
14.0% (AR: 17.6%, AP: 12.6%). Both morbidity and
mortality were related to the age of the patient. Following
anterior resection the operative morbidity and mortality was
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correlation between the grade of the surgeon and morbidity
or mortality.
Crude 5 year survival was 27.6% overall, ranging from
68.1% for Dukes' A tumours to 5.5% in patients with
distant metastases (AR: 81.2% to 0%, AP: 61.3% to 9.1%).
Survival was not related to the distal clearance (AR) or
distance of the tumour from the anus (AP). Local recurrence
occurred in 27.4% (AR: 30.8%, AP: 26.1%). The mean
interval from operation to development of local recurrence
was 18 months (AR: 14, AP: 19). The mean interval from
diagnosis of local recurrence to death was 11 months (AR:
12, AP: 10).
Most reports have been from teaching centres or of a
single surgeon's experience, and have shown lower operative
mortality and better survival rates. Our results therefore give
no cause for complacency.
Radiotherapy for epidermoid anal carcinoma
D. Otim-Oyet, A. Horwich, J. Crow & H.T. Ford
Royal Marsden Hospital, Surrey, UK.
A retrospective analysis on 75 patients treated at the Royal
Marsden Hospital between 1958 and 1986 showed that 29
presented with Lyons T2 tumours and 27 Lyons T3. Twenty
patients (26.6%) had inguinal nodal metastases and 3 sys-
temic dissemination. Definitive treatment was radiotherapy
in 55 patients, 46 of whom received a radical dose of 60Gy/
30*/6 weeks, or NSD equivalent. Four of these had com-
bined modality treatment with SFU and mitomycin-C. Of 20
patients treated by surgery 9 received pre- or post-operative
radiotherapy. The median follow-up of survivors was 49.8
months. The actuarial case specific survival at three years
was 55% and this was adversely influenced by increasing
stage and histological grade. In the radiotherapy group
72.2% (13/18) of TI, T2 no patients were controlled, and 3
of 5 relapsing patients were salvaged by surgery. Five of
eight patients who developed distant metastases also had
uncontrolled primary tumours. Six of 20 (30%) patients
treated by surgery recurred loco-regionally and none were
salvaged by radiotherapy.
It is concluded that radiotherapy alone is effective treat-
ment for small epidermoid anal carcinomas, and has the
advantage of preserving anal continence. More advanced
tumours probably require combined modality treatment.
patients showed renal toxicity, or suffered symptomatic
neurotoxicity or pulmonary toxicity. Seventy-eight cycles in
22 patients have been studied for haematological toxicity.
No cases of WHO grade IV toxicity, septicaemia or
haemorrhage have occurred. In only 3 cycles did the nadir
platelet count fall below 50 x 1061-1.
We conclude that the toxicity of this combination is
minimal and that there can be further escalation of dosage in
patients with high GFR.
Prediction of late renal damage in stage C metastatic
teratoma
G. Duchesne, C. Barton, M. Williams & A. Horwich
Institute of Cancer Research and Royal Marsden Hospital,
Sutton, UK.
Patients presenting with large (>5cm) abdominal metastases
from malignant non-seminomatous germ-cell tumours may
be at particular risk of long-term renal damage from the
combined effects of ureteric obstruction and cisplatin
chemotherapy. Renal function (51EDTA clearance) and the
presence of hydronephrosis (HN) and/or renal cortical
atrophy were studied prior to and following chemotherapy
in 114 patients to identify potential risk factors for late renal
damage. Low EDTA clearance at presentation was signifi-
cantly more common in the presence of HN (21/40 vs. 8/74
without HN, P<0.01). In the absence of HN patients
treated with cisplatin retained acceptable renal function at
the completion of chemotherapy (clearance 102mlmin-1).
Of 32 patients with HN receiving cisplatin, 6 had renal
atrophy at presentation, and 6 developed late atrophy. The
development of atrophy and poor renal function at the end
of chemotherapy were both associated with failure to
improve EDTA clearance by at least 10% after one month
of treatment, and with presenting clearances below normal.
By contrast 7 patients with HN receiving carboplatin showed
an overall improvement in renal function (95 124mlmin-1)
and none developed renal atrophy. Thus hydronephrosis and
low EDTA clearance at presentation, together with failure to
show an early improvement in renal function (through relief
of obstruction) predict for late renal damage, which may be
avoided by the use of carboplatin or possibly by the use of
ureteric stenting in bad risk patients.
Genito-urinary Cancer
Toxicity of a carboplatin, etoposide, bleomycin combination
as primary chemotherapy of metastatic malignant teratoma
R.A. Dealey & T. Sheehan
Velindre Hospital, Cardiff, UK.
In May, 1986 we commenced using the combination of
carboplatin 350mgm-2 day 1, etoposide 120mgm-2 days 1,
2 and 3 i.v. with cycles repeated after 21 days, with
bleomycin 30mg i.m. weekly to a total dose of 360mg.
Subsequently the dose of carboplatin has been increased to
750mg in patients with glomerular filtration rate (GFR)
greater than 90mlmin-1, and later to 900mg where GFR
exceeded 120mlmin- and initial platelet count exceeded
200x1061- .
No major toxicity has been encountered. Nausea and
vomiting have occurred but have not affected delivery of
chemotherapy. Temporary alopecia was invariable. In some
patients skin reactions resulted in cessation of bleomycin. No
Cisplatin-induced renal tubular defects
L.M. Matheson1, J.F. Smyth2 & C.P. Swainson2
1University Department of Clinical Oncology, Western
General Hospital and 2Royal Infirmary, Edinburgh, UK.
Cisplatin administration is known to cause renal tubular
defects. A retrospective survey of 165 patients (aged 11-70
years) treated in Edinburgh (1978-1987) with various cis-
platin regimens has now been completed; all patients received
mannitol and intensive hydration but no routine magnesium
supplementation. Fifteen of 165 (9%) developed asympto-
matic systemic acidosis (plasma bicarbonate <21 mmol -1)
and in 10 patients (6%) mild acidosis persisted. In 2 patients,
recovery occurred after 9 months. Hypomagnesaemia deve-
loped in 103/148 (69%), pre-therapy [Mg]
0.79+0.08mmolI -1, post-therapy 0.56+0.01 mmolI -1,
P<0.0001. In all other patients, plasma [Mg] remained
within the normal range but fell significantly from pre-
treatment levels (pre 0.82+0.07mmolI -1, post
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0.76+0.05mmoll -1, P<0.0001). Relationship between post-
therapy plasma bicarbonate and magnesium levels as below:
Plasma [Mg]mmol-1]
Plasma [bic]mmoll-1 <0.71 .0.71
<21 8 (5%) 4 (3%)
>21 95 (64%) 38 (26%)
There was no correlation between bicarbonate and Mg
levels with cumulative cisplatin dosage (range 100-
900mgm-2). Plasma potassium levels remained unchanged.
The majority of patients develop hypomagnesaemia while
a minority develop tubular acidosis. The incidence and
severity of incomplete renal tubular acidosis is under
investigation.
A report of surveillance of stage 1 seminoma post
orchidectomy
C.J. Tyrrell & F. Daniel
Department of Radiotherapy and Oncology, Plymouth
General Hospital, Plymouth, Devon, UK.
Between April 1984 and December 1987, 35 patients with
seminoma were referred.
All were investigated with serum markers (AFP and
BHCG) lymphogram, CT scan of abdomen and ultrasound
of testes.
Two were excluded because of elevated alpha foetoprotein.
Of the 28 stage 1 patients, 25 were considered to be of
good prognosis and received no adjuvant radiotherapy.
Of these, 3 patients have relapsed (12%) after 5, 6 and 6
months respectively. Mean follow up is now 26 months (6-
50 months).
All patients remain alive and disease-free.
The relapse rate with stage 1 seminoma treated by orchi-
dectomy alone and careful observation may be lower than
stage 1 teratoma and may be a safe alternative to adjuvant
radiation.
Dose of intravesical chemotherapy
J.R.W. Masters
Institute of Urology, University College, London, UK.
The response of tumours to systemic chemotherapy is pro-
portional to the dose rate achieved. Dose rate usually is
calculated as the area under the plasma drug concentration -
time curve (AUC or C xT). In contrast, this concept is not
used for intravesical chemotherapy. Instead, it is the weight
of drug instilled into the bladder that is considered to be the
dose. Thus, a 60mg instillate of ThioTEPA gives a twofold
higher dose than a 30mg instillate, regardless of the volume
of fluid or the period of exposure. The drugs usually are
dissolved in a corresponding volume of solvent, the 60mg in
60ml and the 30mg in 30ml, giving a twofold difference in
'dose', but at identical concentrations of 1 mgml-1. It is
probable that the response of superficial bladder cancer to
intravesical chemotherapy also is proportional to the drug
concentration and period of exposure (CxT). Many pub-
lished studies of intravesical chemotherapy record neither the
drug concentration nor the period of exposure, only the
weight of drug, and consequently optimum doses have not
been calculated. If CxT were used to calculate the dose,
intravesical chemotherapy could be made safer, cheaper and
more efficient, as less drug would be needed to achieve the
same dose. By reducing the volume of instillate to the
minimum quantity required to cover the tumour and urothe-
lium, the patient may be able to tolerate the therapy for a
longer period, thus further increasing the dose rate. These
measures could increase the success rate of intravesical
chemotherapy.
Megestrol acetate as second line hormone therapy in
advanced carcinoma of the prostate
F. Daniel, C.J. Tyrrell & P.M. MacLeod
Department of Radiotherapy and Oncology, Plymouth
General Hospital, Freedom Fields, Plymouth, UK.
Twenty-two patients with advanced metastatic carcinoma of
the prostate previously managed with first line hormone
therapy (orchidectomy, LHRH analogue or diethylstil-
boestrol) have received megestrol acetate 160mg daily, at
disease progression. Patients have been followed up for a
period of up to 36 months with a minimum follow-up of 6
months.
Twenty-one patients are evaluable for toxicity and res-
ponse. The treatment was well tolerated with minimal mor-
bidity. Two patients reported excess weight gain and 2
developed exacerbations of congestive cardiac failure which
stabilized with reduction in dosage of megestrol to 80mg
daily. Eight patients (38%) reported subjective improvement
in their symptoms. An objective response as assessed by
serial rectal examination, bone scanning, X-rays and prosta-
tic acid phosphatase assay according to the criteria of the
NPCP was seen in 6 patients (28%). There were no complete
or partial responses, all responses being stabilization of
disease of 6-12 months duration (mean 40.3+12.8 weeks).
We have reviewed the controversial role of second line
hormonal measures in advanced carcinoma of the prostate
and conclude that megestrol acetate has a useful role and is
as effective as other measures with the advantage of minimal
morbidity.
Localised prostatic carcinoma: A retrospective analysis
comparing radical radiotherapy with hormonal manipulation
T. Joannides, D. Tong, M.R. Jani & H. Kinder
Department of Radiotherapy and Oncology, Guy's Hospital,
Department of Urology, Guy's and St. Peter's Hospitals,
London, UK.
To assess the efficacy of local treatment of carcinoma of the
prostate *at our institution we carried out a retrospective
analysis of patients treated for localised carcinoma of the
prostate (TO-4, NX, MO) between January 1976 and
December 1985. Following initial treatment of obstructive
symptoms with either transurethral resection of the prostate
or retropubic prostatectomy the patients were then allocated
to either radical radiotherapy, orchidectomy, or diethyl-
stilboestrol.
This is an on going analysis which will include over 300
patients but we present an interim report of 43 patients
(mean age: 66 years, age range: 47-79 years) treated by
radical radiotherapy (6,000cGy in 30 daily fractions over 6
weeks), and 30 patients (mean age: 72 years, age range: 53-
84 years) treated by bilateral subcapsular orchidectomy or
diethylstilboestrol.
Local tumour control was significantly better in the radio-
therapy group (76%) compared to the hormone group (45%)
although there was no significant difference in the time to
first systemic disease progression overall. Probability of local
control decreased with poorly differentiated tumours and
T3-T4 tumours fared worst in both groups.
Radiation therapy was tolerated well with a 9% late
complication rate including proctitis, tenesmus, and bladder
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The diagnosis of carcinoma of the prostate, bladder and
kidney by the CA-50 radioimmunoassay test
S.B. Kelly', N.A. Habib', M.J. Hershman2,
R.C.N. Williamson2 & C.B. Wood2
Departments of Surgery, 'Bristol Royal Infirmary and
2Royal Postgraduate Medical School, London, UK.
Carcinoma associated antigen (CA-50) is a tumour asso-
ciated carbohydrate antigen, defined by the monoclonal
antibody C50, which has been raised against a colorectal
adenocarcinoma cell line. The aim of this study was to assess
whether CA-50 can differentiate patients with urological
carcinomas from normal subjects and those with benign
disease. A radioimmunoassay was used for the detection of
CA-50 in the serum of 50 normal subjects, 86 patients with
benign disease and 104 patients with urological carcinomas.
Serum levels in all 50 normal subjects and 83 of 86 patients
(97%) with benign disease were <17U ml-1, while 49 of 104
patients (47%) with carcinoma had levels > 17 Uml-1. Thc
sensitivities for prostatic, bladder and renal carcinomas werc
43%, 62% and 47% respectively. In patients with prostatic
carcinoma, the sensitivities were 0% for well differentiated
carcinomas, 33% for moderately differentiated carcinomas.
67% for poorly differentiated carcinomas and 71% for-
metastatic disease. The sensitivities for non-invasive and
invasive bladder carcinomas were 42% and 89% respectively.
Therefore this test may prove useful in the diagnosis of
patients with urological malignancies.
Head and Neck Cancer
Radiotherapy of paranasal sinus malignancy
B.J. Haylock, G. John & I.C.M. Paterson
Velindre Hospital, Cardiff, UK.
Between 1974-83, 72 cases were referred to this centre. The
mean age was 61 years (range 41-91). The commonest
presenting symptoms were nasal obstruction, facial swelling
and pain. Sixty-five percent had squamous cell carcinoma, of
these 81% arose in the maxillary sinus and 19% in the
ethmoids. Most had advanced disease. Eighty-nine percent of
maxillary sinus cases were UICC stage 3 or 4 at presen-
tation. The majority had radiotherapy alone or pre-operative
irradiation followed by elective surgery. Patients given radi-
cal radiotherapy received 10 fractions, 3 fractions/week or,
20-30 daily fractions over 4-6 weeks, with total doses
between 40 and 60Gy (mean TDF 96).
Actuarial analysis of all squamous carcinoma revealed a 5
year survival of 37.4% and relapse free survival of 31.6%.
For those receiving radical doses the 5 year survival was
46%. Survival was the same for patients receiving radical
radiotherapy alone or pre-operative irradiation and surgery.
Despite fractional doses in excess of 4Gy in some cases, late
radiation damage was confined to 5 cases of ocular damage
(total blindness in one) and one of osteoradionecrosis of the
maxilla.
The optimum treatment of these malignancies continues to
be controversial.
Lonidamine and radiotherapy in head and neck cancer
L. Magnol, F. Terraneol, F. Bertonil, M. Tordiglione2,
D. Bardelli2, M. De Gregorio3 & G.B. Ciottoli3
I0. Alberti Inst., Civil Hospital, Brescia, I; 2Civil Hospital,
Varese, I and 3F. Angelini Research Inst., Rome I, Italy.
Lonidamine (L) an inadazole carboxylic acid derivative was
shown to have an antitumour activity in phase I-II studies in
lung, breast and prostate cancer. L was also shown to
potentiate the effects of X-rays both in vitro and in vivo by
inhibiting the recovery of cancer cells from potentially lethal
damage. Its tolerance was satisfactory when used either
alone or in combination with radiation. Since January 1983,
95 patients with cancer of the oral cavity have been admitted
to this double-blind randomized study. Patients, stratified by
the presence (or absence) of clinically detectable lymph nodes
(N), were allocated to the L+radiotheapy (LRT) or
placebo +radiotherapy (PRT) group. Radiotherapy (1.5Gy
twice daily for 5 days a week by 60Co or 7-12MeV photon
beam) was given up to 60-66Gy on tumour and clinically
affected N. Clinically uninvolved N were irradiated up to
45Gy. L (150mg 3 times daily) was administered for 3
months starting from 3 days before irradiation. Eight-six
patients (42 in the LRT and 44 in the PRT group) were
adequately treated and evaluable for response. Twenty-nine
(69%) and 26 (59%) complete responses (CR) were observed
in the LRT and PRT groups, respectively. The estimated
median duration of CR was > 1,200 days for LRT and 590
days for PRT (P=0.058). Life table % estimate of local
control was significantly superior to the LRT group
(P=0.043). The estimated disease-free patients at 2 years
were 52% and 29% in the LRT and PRT groups, respec-
tively. Neither an increase in the acute reaction to radiation
nor haematological toxicity was observed.
Role of radiotherapy in the suppression of parotid secretions
A.C.R. Robinson', G.G. Khoury' & P.M. Robinson2
'University of Leeds, Department of Radiotherapy,
Cookridge Hospital, Leeds; and 2University of Leeds,
Department of Surgery, Leeds, UK.
Suppression of salivary flow is of value in the management
of salivary fistulae and sialectasia. It may also be beneficial
in mentally defective patients and those with neurological
palsies lacking control of their salivation. Available treat-
ments are anticholinergics, parotidectomy, neuroblastive
procedures and radiotherapy.
Nine cases were treated by irradiation between January
1978 and December 1987, the underlying pathology being
sialactasis (5), traumatic fistulae (2), post-operative parotitis
(1), excessive dribbling in a mentally subnormal patient (1).
Four had previous surgery. The median age was 50 years
(range 21-83). A direct field was applied over the parotid
gland and treatment was given with 250kevy-or Co60. The
mentally subnormal patient had both parotids treated. A
number of different regimes were used from 3 Gy in 6
fractions over 18 days to 30Gy in 6 fractions over 8 days.
Eight patients had complete resolution of symptoms, one
had partial relief and no relapses were seen after a median
follow-up of 26 months (range 1-107 months). Low doses
were as effective as high doses in suppressing salivation.
There were no acute or long term side effects.
Radiotherapy is an effective treatment for these benign
conditions. It avoids long term medication and the need for
surgery, important considerations in the elderly or mentally
subnormal. It can also be of benefit in those who have failed
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Gynaecological Cancer
Carcinoma of vagina: A 15 year experience at a regional
radiotherapy centre
A.C.R. Robinson1, G.G. Khoury' & N. Fazlani2
'University Department of Radiotherapy and 2Regional
Radiotherapy Centre, Cookridge Hospital, Leeds, UK.
Vaginal cancer is rare, prospective studies are difficult to
mount and require the cooperation of many centres. We
reviewed all case notes of patients treated at Cookridge
Hospital over a 15 year period, to identify prognostic
factors, optimal management policy and evaluate treatment
morbidity.
Sixty-three patients, with a median age of 69 years were
evaluated. Follow-up ranged from one to 120 months
(median for survivors 40 months). Sixty had squamous cell
carcinomas and three adenocarcinomas. The actuarial 5 year
survival for cell patients was 32.4%.
In early stages (FIGO I +II) the local control and survival
seen with different treatment policies will be presented. The
influence of stage, histological grade, age and presenting
haemoglobin levels on survival were analysed. Treatment
complications were documented.
The role of lymphography in the post-operative management
of carcinoma of the endometrium
J.D. Graham, P.R. Blake and C. Parsons
Departments of Radiotherapy and Diagnostic Radiology,
Royal Marsden Hospital, London, UK.
In order to assess the role of lymphography in the post-
operative management of carcinoma of the endometrium 57
consecutive cases were analysed retrospectively. Four
patients with recurrent disease were excluded. Of 53 patients,
48 had undergone TAH&BSO and 5 D&C only. Distribu-
tion by clinical stage was: 40 stage I (75%), 8 stage 11(15%),
3 stage III (6%) and 2 stage IV (4%). Bipedal lymphography
was performed in 41/53 cases (77%).
There was unilateral pelvic lymphadenopathy detected in 3
cases (2 stage I, 1 stage II). No case of para-aortic node
involvement was seen. The use of post-operative radio-
therapy either by intracavitary therapy alone or in combi-
nation with external beam is made on the basis of stage,
histological grade and depth of myometrial invasion. In no
case did lymphography alter the management decision made
on the basis of these criteria, although the 3 cases with
positive lymphograms received an additional 5Gy to the
involved side of the pelvis. In a short median follow-up of 9
months, a total of 4 cases have relapsed (2 stage I, 2 stage
II). All had normal lymphography at presentation and
received both external beam radiotherapy to the pelvis and a
single intracavitary vault insertion. The pattern of relapse
was: Pelvis alone 1, pelvis and lung 2, lung alone 1 and was
related to tumour grade.
Bipedal lymphography has no role in the post-operative
management of carcinoma of the endometrium.
Intraperitoneal Yttrium-90-labelled antibodies in ovarian
cancer
J.S.W. Stewart, V. Hird, H.E. Lambert & A.A. Epenetos
Imperial Cancer Research Fund and Department of Clinical
Oncology, Hammersmith Hospital, London, UK.
Between March 1987 and March 1988, 20 patients with
ovarian cancer received intraperitoneal Yttrium-90-labelled
monoclonal antibodies to tumour associated antigens. Blood
and urine Yttrium-90 activities were monitored for 5 days
after treatment. The non-specific radiation dose to the
peritoneal cavity was measured by lithium fluoride thermo-
luminescent dosimetry. Yttrium-90-labelled antibodies were
absorbed from the peritoneal cavity into the systemic circula-
tion with 20% of the injected dose at 40h. Bone marrow
suppression is the dose limiting factor with moderate toxicity
after 15cCi Y-90-labelled monoclonal antibody. The esti-
mated radiation dose to the marrow from the circulating
Yttrium-90-labelled antibody was <50cGy. Bone marrow
irradiation from unchelated Yttrium-90 absorbed onto bone,
may account for the discrepancy between the estimated
radiation dose to marrow and observed toxicity. Although
this was primarily a phase I study we observed a partial
response in 1 out 5 patients with tumour nodules <2cm in
diameter.
Chemotherapy in cervical carcinoma
S. Powell
For the London Gynaecological Oncology Group, UK.
The poor survival of FIGO stage Ilb, III, IV and early stage
node positive cervix cancer has led to interest in chemo-
therapy in addition to standard methods of local treatment.
We studied four chemotherapy regimes in patients with re-
current cervix cancer.
One hundred and twenty-five patients received treatment:
(1) 41 received single agent ifosfamide (1.5gm-2, days 1-5);
(2) 39 received ifosfamide (as (1)) and cisplatinum
(50mgm-2, day 1); (3) 28 received cisplatinum (20mgm-2,
days 1-3), etoposide (120mgm 2, days 1-3) and bleomycin
(15mg, day 1); (4) 11 received cisplatinum (as (3)), metho-
trexate (100mg, day 1) and bleomycin (15mg, day 1); (5) 6
others received cisplatinum alone or in other combination.
Treatment schedules were repeated 3 weekly.
Three patients in (1) and six patients (3) had adeno-
carcinoma. None of these responded and were excluded.
Response rates were: (1) 33% (12/36); (2) 38% (12/31); (3)
40% (8/20); (4) 30% (3/10) and (5) 60% (3/5). Comparative
haematological, renal and neural toxicity will be presented.
When chemotherapy was given neo-adjuvantly, response
rates were higher: treatment (3) 67% (6/9) and treatment (4)
57% (4/7). Active agents have been found for squamous
carcinoma of the uterine cervix, but combination chemo-
therapy has not led to significantly enhanced efficacy.
Pelvic field irradiation: An investigation of accuracy of
treatment delivery
S.E. Griffiths & G.G. Khoury
Regional Radiotherapy Centre and University Department of
Radiotherapy, Cookridge Hospital, Leeds, UK.
In previous studies 16% of supine and 26% of prone pelvic
treatments using skin marks showed a lateral shift of 10mm
or more.
Fifteen patients receiving pelvic irradiation were studied to
see if reproducibility could be improved by using lateral
alignment lasers. Films were taken at the initial treatment
simulation and on 4 subsequent occasions. Patients were set
up initially without and then with the use of lateral lasers
and films taken for comparisons.
Also, using a body phantom, we have measured shifts
occurring with differing degrees of lateral rotation.
In comparison with our initial study we find that the
magnitude and frequency of lateral shift errors is less, and
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Clinically significant caudo-cephalic shifts of up to 2cm
are seen and we are currently studying means of reducing
these errors.
Our experience will be presented and discussed together
with recommendations for optimising treatment delivery.
The use of transvaginal and transrectal endosonography to
assess vaginal tumour
J.E. Browning & E.C. Whipp
Radiotherapy Centre, Bristol, UK.
Current methods of assessment of vaginal tumour include
examination under anaesthetic and computerised tomo-
graphy. Magnetic resonance imaging is being evaluated.
In this study, 8 patients with vaginal tumour were endo-
sonographically assessed. Three had primary vaginal car-
cinoma and secondary tumour arose from the cervix (2),
colon (2) and bladder (1).
The patients were unanaesthetised and had not micturated
for 1 h. A Bruel and Kjaer type 1846 scanner was used.
Transvaginal sector scanning was performed in the supine
position with the 7MHz 8537 probe. The site, depth and
extent of tumour could be demonstrated and measured. For
gynaecological tumours a FIGO or T(NM) staging was
derived. A transrectal radial probe (type 1850 with a
5.5 MHz 90 degree transducer) was introduced with the
patient in the left lateral position. It demonstrated the
integrity or otherwise of the rectal wall.
All patients were treated by radiotherapy.
Endosonography is a simple, convenient and well tolerated
procedure. It gives accurate information on local tumour
extent upon which treatment modality and dosimetry may be
based.
Tumour regression after treatment may be monitored by
this method.
Paediatric and Lung Cancer and Palliation
Clinico-pathological review of cases registered as primary
malignant tumours of the liver in children in the West
Midlands between 1957-1986: A West Midlands Regional
Children's Tumour Registry (WMRCTR) study
S.E. Parkes, A.H.C. Cameron, K.R. Muir, J.R. Mann,
F. Raafat, J.R. Pincott, N. Kasthuri & L.C. Ingram
Birmingham Children's Hospital, Birmingham, UK.
Fifty-six children identified by the Birmingham and West
Midlands Regional Cancer Registry as having primary
malignant tumours in the 30 years 1957-1986 in the West
Midlands RHA area (pop. 1.2 M children), were reviewed
during data collection for the WMRCTR. Eight cases were
excluded owing to age (3) and residence (5).
After pathological review, 4 groups of tumours arising in
the liver were identified: Hepatoblastoma (25), hepatocellular
carcinoma (2) [='classical liver tumours']; rhabdomyo-
sarcoma (10); yolk sac tumour (3). Cases of metastatic
neuroblastoma (2), non-Hodgkin's lymphoma (1), mesen-
chymal hamartoma (1), cirrhosis (1) and neonatal hepatitis
(1) were excluded. Two cases are still under review.
Commonest symptoms in the 27 classical liver tumours
were large liver, swollen abdomen, fever, anorexia and
vomiting. Fifteen presented in the right lobe, 1 midline, 1 in
the left, 8 bilateral and 2 unspecified. Distant metastases
were present in 7 cases. Surgical procedures consisted of
resection (14), biopsy (10) and none (3). Fifteen patients had
chemotherapy, 6 radiotherapy and 6 both. One of the
hepatoblastoma patients died at birth. Twenty-six percent of
these children had a congenital abnormality or other recog-
nised predisposing factor: Beckwith's syndrome (1), hemi-
hypertrophy (2), polyposis coli (1), tyrosinosis (1), renal
dysplasia (1) and undescended testis (1).
Main symptoms in the remaining 13 children were large
liver, anorexia and abdominal pain. Three tumours arose in
the right lobe, 2 in the left, 4 were bilateral and 4 unspeci-
fied. Distant metastases were present in 9 cases. Four of this
group underwent resection, 9 having biopsy alone. Five had
chemotherapy, 6 radiotherapy and 2 both. There were no
associated malformations or syndromes in this group
although the maternal grandmother of one child with
rhabdomyosarcoma had breast cancer, which could be indi-
cative of Li-Frau meni syndrome. Long term survival was
seen only in hepatoblastoma, with 6 (25%) of the patients
still alive >5 years after diagnosis (range 5 to 21 years).
Workload patterns at the Children's Hospital, Birmingham
(BCH) - Oncology a regional speciality
R.J. Wilde1, K.R. Muir2 & J.R. Mann3
'Department of Community Medicine, Central Birmingham
Health Authority; 2West Midlands Regional Children's
Tumour Registry, Birmingham Children's Hospital; and
3Department of Oncology, Birmingham Children's Hospital,
Birmingham, UK.
BCH has been stretched beyond its limits, in terms of
accommodation, manpower and funding. The growth in
designated regional specialties (DRS), of which there are 17,
is probably largely responsible for this. These use 50% of the
hospital beds and provide specialist care for children in the
West Midlands Health Authority Region. As a case in point,
we have examined oncology to investigate a workload
increase of 20% in 5 years observed through hospital activity
analysis (HAA). Oncology is the largest DRS (26% of DRS
bed usage in 1986) thus warranting further study.
Information collected by HAA was supplemented by data
collected by the West Midlands Regional Children's Tumour
Registry. Variables studied to assess changes in workload
with time included childhood population, cancer incidence,
referral patterns, survival rates and the effect of shared care.
The results showed that both childhood population (1.01
million in 1986) and childhood cancer incidence (146 cases
per million per year during 1975-1985) have remained
relatively constant in recent years. However, increases were
found in the referral rate to BCH (from 49% of cases in
1975, to 71% of cases in 1985) and in survival rates (e.g. 3-
year survival for leukaemia increased from 53% in 1973, to
65% in 1983). Shared care was also found to have increased
(from 4% in 1980, to 27% in 1986).
In conclusion, the increased workload of paediatric onco-
logy at BCH may most readily be explained by increases
seen in referral and survival rates partially counteracted by a
simultaneous increase in shared care. Such explanations
suggest a successful service.
A phase II study of actinomycin-D in small cell lung cancer
E. Cornford & D.A.L. Morgan
Hogarth Centre of Radiotherapy and Oncology, General
Hospital, Nottingham, UK.
Actinomycin-D has a wide spectrum of activity against solid
tumours, but there is almost no published data on its activity
against small cell lung cancer (SCLC), one of the most
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tively inexpensive, a consideration of increasing importance
at the present time. A study was therefore conducted to
assess its activity in patients with SCLC.
Fourteen patients with previously-untreated, measurable,
extensive-stage SCLC received actinomycin-D, 50mcgkg-
i.v., repeated at 21 day intervals. Treatment was discon-
tinued, and more conventional therapy instituted at any
signs of tumour progression, or if there were no objective
signs of response, using UICC guidelines, at the time that
the third cycle was due.
No objective responses were seen; gastrointestinal toxicity
was moderate (grades II-III) in most cases; no significant
haematological toxicity was seen.
Actinomycin-D, as administered here, is lacking in activity
in SCLC.
A numerical discriminant applied to prediction of survival in
inoperable carcinoma of the bronchus
J. Thorogood, T.M. Collins, D.V. Ash & H.J. Close
Cookridge Hospital, Leeds, UK.
An evaluation of the palliative role of radiotherapy in
inoperable lung cancer revealed that 16 out of 96 patients
studied (17%) were dead within 3 months of treatment and
were unlikely to have benefited from therapy. In order to try
and identify these patients prospectively a statistical discrimi-
nant approach was used to formulate a suitable index to
predict survival to 3 months. This index comprised weight
loss in the previous 6 months, performance status, extent of
disease and blood lymphocyte count.
A simple tree diagram was developed for clinicians to
follow-through for a given patient, to arrive at one of 16
discrete probabilities of that patient being alive 3 months
later. No calculations are required for its use and it is based
on the index, using 4 factors only. The survival probabilities
ranged from over 0.95 for 3 or 4 factors in the good
prognosis category, to <0.20 with 3 or 4 factors in the poor
category.
When applied to a prospectively collected set of 80
patients, the index achieved an accuracy of 97% in predict-
ing those who would survive for longer than 3 months. It
achieved a low accuracy of 26% in those dying before 3
months because these cases presented with 2 good factors
and 2 poor.
Palliative radiotherapy for bone metastases: Why don't
British radiotherapists give single fractions?
E.J. Maher, A. Marks & A. Crellin
Regional Centre for Radiotherapy and Oncology, Mount
Vernon Hospital, Northwood, Middlesex, UK.
Forty-two radiotherapists were asked about treatment of a
theoretical patient with thoracic spine metastases from breast
cancer. Fifteen of 42 would give I fraction, 19, 2-5, and 8,
6-10. Fifty-three percent of those from the North and
Midlands gave single fractions, compared with 26% of those
from London and the South. Reasons for fractionation
included: Training (63%), departmental policy (44%), acute
side-effects (37%), fears about recurrence and retreatment
(37% each). Reduction of late damage (19%), perceived
improved healing (11% 0/), and better tumour regression (26%)
were less influential. Single ;fractions might be used if there
was machine-pressure (82%), patient lived a long way away
(70%), or was 70+ (74%), the primary was lung not breast
(63%), or metastatic site was outside the vertical column
(100%). Non-fractionators' reasons included training (67%),
with departmental policy less important (13%). Most would
fractionate in the presence of neurological symptoms (73%),
but young age (13%), bone destruction (20%) and first
metastatic site (33%) were less persuasive.
Despite published evidence that single doses of RT
provide safe and effective palliation, this study confirms the
preference for multiple fractions and highlights confusion
about the scientific basis for this.
A pain survey in an out-patient cancer clinic
E. Cornford & D.A.L. Morgan
Hogarth Centre of Radiotherapy and Oncology, General
Hospital, Nottingham, UK.
That pain is a common symptom in cancer patients is well
known. A survey was conducted to assess the extent of the
problem in one radiotherapy and oncology practice.
Two hundred and seven consecutive out-patients with
cancer (both new referrals and follow-ups) were asked if they
were in pain at the time of clinic attendance, and if so,
marked an assessment of its severity on a 10cm visual
analogue scale (VAS). Patient and tumour details and anal-
gesic consumption were documented. The attending
physician recorded whether the pain was likely to be due to
cancer.
The data so obtained are summarised in the Table:
No. in Mean Taking
Tumour No. of Mean pain VAS Tumour anal-
site patients age (%) (cm) pain gesics
Lung 73 65 25 (34) 4.2 22 19
Breast 58 60 23 (40) 4.3 17 15
Other 76 61 25 (33) 3.8 14 17
Total 207 62 73 (35) 4.1 53 51
Hemibody irradiation (HBI) for metastatic bone pain
P.J. Hoskin, C.L. Harmer & H.T. Ford
Royal Marsden Hospital, Sutton, Surrey, UK.
Thirty-eight patients treated between January 1979 and
December 1987 with HBI for multiple sites of bone pain
from metastatic disease have been reviewed. Forty-six indivi-
dual treatments were given, 15 upper body (UHBI) and 31
lower body (LHBI). Administered doses were UHBI; 6Gy
mpd (14 patients), 7Gy mpd (1 patient), and LHBI; 8Gy
mpd (29 patients), 6Gy mpd (1 patient), 4Gy mpd (I
patient), delivered in a single fraction at a dose rate of 0.15-
0.2Gymin-1. Twenty-three patients had primary prostatic
carcinoma (PC), 13 had myeloma (MM), 1 had an osteo-
sarcoma and 1 metastatic melanoma. Response has been
assessed retrospectively and defined as an improvement in
pain with stable or reducing analgesic requirements. Overall
response rate was 83%; 25/29 (86%) of treatments for PC
and 12/15 (75%) of treatments for MM. Three complete
responses were seen (i.e. complete resolution of pain and no
analgesic requirements); 2 with PC and 1 with MM. Four-
teen of 15 (93%) of UHBI responded and 23/70 (77%) of
LHBI responded. Mean overall survival from HBI was 8.9
months (range 1-36); in patients with MM mean survival
was 10.2 months (range 1-36) and in PC was 5.3 months
(range 1-19). Six patients with MM are currently alive (mean
survival from HBI 12.2 months) and 1 with PC is alive 3
months from HBI. Significant toxicity occurred in 26
patients (68%) with one fatality from pneumonitis following
UHBI. Six patients subsequently had further local radio-
therapy within the previously treated hemibody area without
complications.THIRD MEETING OF THE BRITISH ONCOLOGICAL ASSOCIATION 545
Haematological Neoplasia and Sarcomas
Severe lung toxicity following weekly low-dose chemotherapy
regimen in patients with non-Hodgkin's lymphoma
M. Quigley, M. Brada & A. Horwich
The Royal Marsden Hospital and Institute of Cancer
Research, Sutton, Surrey, UK.
In 1985 and 1986 we carried out a phase II study of a new
chemotherapy regimen alternating low-dose cyclosphamide
and mitoxantrone with bleomycin and vincristine and con-
tinuous oral prednisolone. The regimen was designed for
poor prognostic category patients with non-Hodgkin's lym-
phoma (NHL), who were either elderly or had recurrent
intermediate or high grade NHL.
Nineteen patients were treated and 6 developed unex-
pected lung toxicity 8-10 weeks after start of chemotherapy.
The pneumonitis was fatal in 5 patients. This occurred at
bleomycin doses <50U m-2 and cyclophosphamide < 1,875
mgm-2.
Thirty-five percent incidence of apparent drug induced
pneumonitis following low doses of bleomycin in evaluable
patients suggests an increased susceptibility to drug induced
pulmonary damage in patients with non-Hodgkin's
lymphoma.
malignant disease. A proportion (25%-40%) of patients
display persistent thrombocytopenia after ABMT. An auto-
immune basis for this delay in recovery of peripheral cell
counts has been postulated and a high incidence of cell
specific antibodies to platelets (52%) and neutrophils (65%)
has been detected in the. early post-graft platelet count
recovery post allogenic bone marrow transplantation. Poten-
tial factors of relevance to the formation of autoantibodies
include the patient's underlying malignancy, pregraft chemo-
therapy and/or radiotherapy, in vitro damage to stem cells
during graft storage, the engraftment procedure, insufficient
numbers of inadequately functioning T-lymphocyte suppres-
sor cells in the early post-graft period and post-graft blood
component transfusions. The use of recombinant GM-CSF
to accelerate the rate of recovery of peripheral blood counts
post ABMT may be associated with the development of
platelet-associated immunoglobulins. Prolonged thrombo-
cytopenia post ABMT increased the patient's risk from
bleeding, either spontaneous or associated with sepsis, and
increases the risk associated with prolonged blood com-
ponent transfusion requirement. The administration of intra-
venous immunoglobulin is an established modality of
therapy in idiopathic thrombocytopenic purpura. We discuss
the format of a pilot study to ascertain whether intravenous
immunoglobulin therapy can accelerate delayed platelet reco-
very post ABMT and some initial data from one such study.
A comparison of gallium SPECT and CT in mediastinal
Hodgkin's disease
S. Karimjee, M. Brada, J. Husband & V.R. McCready
Royal Marsden Hospital and Institute of Cancer Research,
Sutton, Surrey, UK.
The aim of this project was the study of the role of high
dose gallium (Ga-67) scanning in the assessment of medias-
tinal Hodgkin's disease (HD).
Comparison of thoracic CT and Ga-67 single photon
emission computed tomography (SPECT) images was under-
taken using high dose Ga-67 in patients with biopsy proven
HD at presentation and after treatment.
Sixteen patients with HD had pre-treatment CT scan and
Ga-67 SPECT studies. In 15 patients all sites of disease
demonstrable on CT were also shown on SPECT scan; in
one patient only one of three sites of disease shown on CT
scan was Ga-67 positive. In three patients four sites demon-
strated on SPECT were not seen on CT scan. Overall of 24
Ga-67 positive mediastinal sites, 4 were not detected on CT.
A number of patients underwent post-treatment assessment
as part of a prospective study.
The apparent 16% false negative rate for CT compared to
SPECT suggests an additional role for high-dose Ga-67
imaging in the initial staging of HD. Early post-treatment
results also indicate that G-67 scanning may help in detect-
ing residual mediastinal disease.
Therapy of immune-mediated thrombocytopenia post
autologous bone marrow transplantation - A pilot study
F.J. Gilesi, A.C. Newland2 & A.H. Goldstone2
Departments of Haematology, 'University College/Middlesex
Hospital and 2The London Hospital, London, UK.
Autologous bone marrow transplantation (ABMT) is an
established procedure in the therapy of haematological
Lung toxicity of melphalan and steroid combination therapy
in multiple myeloma
F.J. Giles', C.R.J. Singer', A.H. Goldstone', J.S. Tobias2 &
J.D.M. Richards'
Departments of 'Haematology and 2Radiotherapy, University
College Hospital, London, UK.
As reported elsewhere at this meeting, we have found upper
hemi-body irradiation (UHBI) to be an effective, well toler-
ated therapeutic modality in advanced multiple myeloma.
This procedure involved the administration of a median dose
of 7.5Gy from a slow cobalt source to the upper body in 35
patients, 18 of whom also received lower HBI. In this series,
the only procedure related death that occurred was attri-
buted to radiation-induced pneumonitis. Three other patients
were also diagnosed as having post therapy pneumonitis, 2
of whom required and responded to oral corticosteroid
therapy. This gave a total incidence of overt symptomatic
pneumonitis of 14% following UHBI in this series of heavily
pre-treated multiple myeloma patients. In order to delineate
the extent of therapy-induced pneumonitis, we have begun to
do baseline lung function tests before the UHBI procedure
followed by sequential tests in the post therapy period. In 7
of the initial 10 (non-smoking) patients who had lung
function tests performed prior to their UHBI obstructive
ventilatory defects were demonstrated, 1 patient having a
combined obstructive and restrictive ventilatory defect show-
ing 2.31 loss of lung volume and 0.351 air trapping. The
other 6 patients had air trapping ranging from 0.4 to 1.451.
The median number of courses of melphalan/prednisolone
therapy received by these patients was eight. All had suffered
occasional lower respiratory tract infections during this
therapy. No other recognised risk factors for lung damage
were elicited on detailed history taking in this patient group.
These initial data have led us to initiate a systematic
programme of lung function assessment in our myeloma
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Alpha interferon therapy of essential thrombocythaemia
F.J. Giles & A.H. Goldstone
Department of Haematology, University College and
Middlesex Hospitals, London, UK.
The efficacy of alpha interferon in the control of the elevated
platelet count which is a feature of a sub-group of patients
with CGL has been noted. We have extended our use of
interferon from this indication and assessed its efficacy in
essential thrombocythaemia (ET) both in a pilot study and
in an ongoing collaborative clinical study. We have now
achieved a platelet count of 600 x 109 1-1 in 11 of 12
sequentially referred patients with ET. The remaining patient
for personal reasons will not permit the administration of an
adequate amount of interferon therapy. A normal platelet
count was achieved in the relevant patients in all cases
within 8 weeks of commencement of therapy at a dosage of
3 Mu daily s.c. with a dosage increment to 5Mu daily if
required after 2 or 4 weeks therapy. On this pilot study
dosage reduction, because of adverse side effects, has not
been required during the phase of induction of a normal
platelet count. We have begun a clinical trial to assess the
long term efficacy of alpha interferon in ET.
Prospective study of infections in multiple myeloma and
related disorders
R.M. Hargreaves & J.R. Lea
John Radcliffe Hospital, Oxford, UK.
A group of 76 patients with multiple myeloma, 13 patients
with Waldenstrom's macroglobulinaemia and 15 patients
with monoclonal gammopathy of uncertain significance
(MGUS) were followed prospectively for a period of up to
twelve months to assess their rate of infections and to
identify possible infection predictors. Infections were classi-
fied according to severity as trivial, moderate or major, the
latter two groups representing potentially life threatening
events. During the twelve month study period, there were 17
deaths of which 10 were directly attributable to infection.
There were 20 episodes of major infection in 17 patients (13
pneumonia, 5 septicaemia, 2 pyrexia of unknown origin); 31
episodes of moderate infection in 25 patients (14 originating
in the respiratory tract) and 54 episodes of trivial infection.
There was a clear seasonal variation in moderate and trivial
infections (the majority occurring in the period November-
April) while major infections were evenly spread over the
year. Most patients with myeloma were immunosuppressed
(non-paraprotein immunoglobulin levels below the lower
limit of normal) while only a minority with Waldenstrom's
macroglobulinaemia and MGUS were. In the group of
patients with multiple myeloma, there was no clear relation-
ship between presence or degree of immunosuppression and
susceptibility to infection. Other features investigated
included smoking habits, paraprotein class, disease stage at
diagnosis and chemo/radiotherapy at the time of infection,
but no significant correlations with infections were found.
Pre-operative chemotherapy in malignant fibrous
histiocytoma of bone (MFHB)
H.M. Earl, L. Morittu, D. Miles, J. Pringle, H. Kemp &
R.L. Souhami
London Supra-Regional Bone Tumour Service, University
College Hospital, London, WC] 6AU and Royal National
Orthopaedic Hospital, Stanmore, Middlesex, UK.
Malignant fibrous histiocytoma of bone (MFHB) is usually
treated by surgery alone, and published series show a five
year survival rate of only 30% (Capanna et al., Cancer, 54,
177 (1984)). Recent reports have indicated that this rare
tumour 'may be responsive to chemotherapy. Since 1985 all
cases of MFHB presenting to the London Supra-Regional
Bone Tumour Service have been treated on a protocol of
pre- and post-operative chemotherapy. Patients were aged
33-69 years, 2M and 4F, and tumour sites were distal femur
(4), distal tibia (1), and superior pubic ramus (1). Patients
were treated with methotrexate 48gm 2 on day 1, and
ifosfamide 3gm-2, with doxorubicin 60mgm-2 on day 10 of
a 28 day cycle. Two courses were given prior to surgery, and
2 courses post-operatively. All 4 patients with distal femoral
lesions had successful endoprosthetic replacement, one had
below knee amputation, and one had complete resection of
tumour of the superior pubic ramus. Histopathological
analysis revealed that 2 patients had complete tumour necro-
sis, 2 had >95% tumour necrosis, and only 2 patients had
little evidence of response to chemotherapy. All patients are
alive and disease-free 2-30 months after surgery. One patient
developed CT scan evidence of pulmonary metastases 6
months after surgery, and achieved a complete response to
ifosfamide and doxorubicin. This report demonstrates that
MFHB is a chemosensitive bone tumour. Patients with this
disease should be included in defined protocols to determine
if long term survival is improved by adjuvant chemotherapy.
Feasibility of retreatment of previously irradiated soft tissue
sarcomas of the limb and limb girdle
J.D. Graham, M.H. Robinson & C.L. Harmer
Department of Radiotherapy, Royal Marsden Hospital,
London, UK.
Ten patients with soft tissue sarcomas of the limb or limb
girdle have been re-irradiated on 12 occasions for local
recurrence following previous limb conserving treatment. The
histological types were: Liposarcoma (5), fibrosarcoma (2),
malignant fibrous histiocytoma (1), rhabdomyosarcoma (1),
synovial sarcoma (1) with 6 tumours being of high grade
malignancy. Retreatment was given with palliative intent in
5/12, and with curative intent following marginal excision in
7/12, at a median time of 15 months after initial treatment
(range 8-324 months). Initial radiotherapy was given at
doses ranging from 1,362-1,941 ret (median 1,650 ret, dose
range 33-60Gy) whilst for retreatment the curative group
received a median 1,768ret (dose 33-60Gy) and the pallia-
tive group a median 1,303ret (dose range 12-5OGy). Initial
local control was achieved in 7/10 of patients and eventually
following 8/12 courses (median duration of local control 9
months); one patient being controlled by further surgery and
radiotherapy. Three patients died from metastatic disease
with local control at the primary site. Early toxicity was not
severe with most desquamation in 2/12. Late toxicity was
severe in 1 case following the third treatment with late
radionecrosis requiring amputation. Moderate oedema and
diminished limb function were seen in 2 cases. Re-irradiation
of the limb and limb girdle appears to be well tolerated and
offers an alternative to amputation for local relapse follow-
ing previous radical multimodality therapy.
The role of radiotherapy in the management of intracranial
meningiomas: The Royal Marsden Hospital experience
J. Glaholm & H.J.G. Bloom
Department of Radiotherapy and Oncology,
Royal Marsden Hospital, Surrey, UK.
One hundred and sixty patients with intracranial meningio-
mas were treated by one consultant at the Royal Marsden
Hospital between 1958 and 1983 with megavoltage photon
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to a target volume comprising the known volume of disease
including a macroscopically clear surrounding margin.
Photon energies from 2 Mv to 8 Mv were employed.
Survival parameters were measured from the time of
diagnosis. Overall 10 year actuarial survival was 50% in all
cases with an overall disease free survival of 60%. Consider-
ing only death from meningioma, the corresponding cause
specific actuarial survival was 65%.
Prognosis was related to the extent of initial surgical
resection. Of those who underwent subtotal tumour resection
with subsequent minimal residual disease, the 10 year
actuarial survival was 70%. Where only partial resection was
possible the corresponding survival was 60% and in inoper-
able patients treated by radiotherapy alone 45%. Eighteen
patients underwent complete resection of disease prior to
irradiation with a resultant 10 year survival of only 20%
owing to the high incidence of adverse histological subtypes
in this group which included malignant meningioma, all of
whom died within 5 years of diagnosis. These differences are
statistically significant.
Performance status at the time of referral for post-
operative radiotherapy was measured retrospectively using
the Karnovsky scale. Patients with a performance rating of
80-100 had a 70% 10 year survival, whereas those with a
score of less than 80 had a 40% survival. The difference is
statistically significant.
Patients undergoing complete surgical resection and not
requiring adjuvant irradiation have an inherently good prog-
nosis. It is therefore not possible to select an appropriate
control group; however, the long term survival of irradiated
patients in this series supports the benefit of postoperative
radiotherapy in patients with residual disease.
Conference Lecture
The biological basis of radiation fractionation
J. Denekamp
Gray Laboratory of the Cancer Research Campaign, Mount
Vernon Hospital, Northwood, Middlesex, UK.
The rationale for giving radiotherapy as a series of small
doses instead of a single treatment has been developed long
after it became common clinical practice. It is not at all clear
whether the current 2.0-2.5Gy per day for 4-7 weeks is
optimized.
Recent experimental data have emphasized that differences
in the response to repeated treatments exist in late reacting
tissues compared with acutely responding tissues and
tumours. It is therefore inappropriate to select new therapies
based on therapeutic differences between skin and tumours.
The relevant comparisons must be made with slowly prolifer-
ating tissues, e.g., lung or kidney.
The experimental data highlighting the differences in
repair capacity and in regenerative capacity will be reviewed.
The influence of reoxygenation and redistribution around the
cell cycle between fractions will also be discussed.
These concepts have led to a new clinical regime -
CHART - at Mount Vernon Hospital, involving 36 fractions
given three times a day, with minimum interfraction intervals
of 6h and no break for the weekend. The biological basis of
this trial and the criticality of the different elements will be
presented.
Bob Champion Cancer Trust Lecture
Clinical and in vitro evaluation of JM8 (carboplatin) and
JM9 (CHIP) in high grade glioma
C.J. Twelves1, J.L. Darling3, K.P. Healey3, D. Miles',
C. Ash2, D.G.T. Thomas3 & R.L. Souhami2
IGuy's Hospital, 2University College Hospital and 3Institute
of Neurology, London, UK.
We have evaluated JM8 and JM9 in the treatment of high
grade glioma, firstly in a phase II clinical study and
secondly, by in vitro chemosensitivity assay.
Fifteen patients were treated (7 grade III and 8 grade IV)
with JM8 or JM9. All had relapsed after surgery and either
radiotherapy alone (3 pts) or radiotherapy and chemotherapy
with procarbazine, CCNU and vincristine (12pts). Median
age was 45 yrs and ECOG score 2. Chemotherapy was JM8
400mgm 2 (10 pts) or JM9 300mgm-2 (5 pts) given every 4
weeks; response was assessed by CT scan: The response rate
was 2/15 (1 response to JM8 and 1 to JM9). Myelo-
suppression was considerable and 3 patients developed grade
IV neurotoxicity.
Chemosensitivity was assessed in 8 short-term cultures
derived from biopsies in a separate group of patients with
malignant glioma, by a 35 S-methionine uptake assay. The
ID50s ranged from 0.02 to 3.7,ugml-' for JM8 and 0.008 to
2.8 ugml-1 for JM9. There was evidence of cross resistance
between the two agents, but no evidence of cross resistance
with CCNU. The range of sensitivities observed for JM8 and
JM9 were comparable to those observed for cis-platinum in
earlier studies.
JM8 and JM9 have activity against high grade glioma
both clinically and in vitro, but toxicity was significant in
this group of poor prognosis patients. Further evaluation of
JM8 should be in good performance status patients.
Biological basis of drug sensitivity and resistance
A.L. Harris
Department of Clinical Oncology, University of Oxford, UK.
Although many tumours are curable with radiotherapy and/
or chemotherapy, the majority of cancer patients die from
their tumour with failure of local control or systemic recur-
rence. Tumours may be resistant de novo (primary resistance)
or resistance may occur in recurrent tumour after initial
response (secondary resistance). It is not known if the
mechanisms are the same. The activity of the various
treatments without excessive normal tissue toxicity implies
that normal tissues are often more resistant than the
tumours. It is not known which regulatory mechanisms
control normal resistance and whether these mechanisms are
important in tumour resistance or differential sensitivity of
tumours. We have used two approaches to this problem:
1. Isolation of mammalian cell mutants hypersensitive to
anticancer drugs
We have isolated a series of 19 different Chinese hamster
ovary cell lines that are many fold more sensitive than
normal for a range of cytotoxic agents. These include
mitomycin-C, monofunctional and bifunctional alkylating
agents, cisplatinum, radiation, bleomycin, m-AMSA, adria-
mycin, VP16, CCNU, vincristine, vinblastine, actinomycin-
D. The CHO mutants were isolated by a replica plating
method following EMS mutagenesis. They are being trans-
fected with human genomic DNA to isolate human genes
regulating the basal drug resistance mechanisms. Three
mutants have been transfected back to wild-type and second-
ary transfections are in progress. A range of defects has been
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defects in single strand DNA break and double strand break
repair, cross-link repair and spontaneous hyper and hypo-
mutability has been shown. The mutation rate findings
suggest both error prone and error correcting mechanisms
are present in mammalian cells.
2. Isolation of mammalian cell mutants resistant to
anticancer drugs
CHO cells were made resistant to chlorambucil by repeated
incremental exposure. They are cross-resistant only to mel-
phalan and nitrogen mustard and to a small extent ifosfa-
mide. They were found to have a marked increase in a
cytoplasmic protein which protects it against the toxicity to
the alkylating agents. This was a particular glutathione
transferase, known as Yc and is representative of a family of
over 10 different types of glutathione transferases, so this is
the first demonstration of a protective function for a specific
transferase against a cross-linking alkylating agent.
Approaches aimed at either inhibiting transferases or using
transferase-activated drugs may greatly increase the thera-
peutic index of alkylating agents. Isolation of the genes
regulating some of these pathways will enable investigation
of the mechanism responsible for sensitivity and resistance
and may provide new targets for therapy.
Symposium: Biology of Tumour Vasculature
and Metabolism
The effect of vasoactive drugs on the fraction of hypoxic
cells in experimental tumours and consequent alteration in
the effectiveness of bioreductive radiosensitizers and
chemotherapeutic agents
I. Stratford, J. Bremner, S. Cole, J. Godden & G.E. Adams
MRC Radiobiology Unit, Chilton, Didcot, Oxfordshire, UK.
It has been shown that administration of hydralazine to mice
induces severe hypoxia in experimental tumours of various
types. In principle, the induction of severe hypoxia in
tumours by manipulation of blood flow can be exploited for
enhancing the efficacies of some chemotherapeutic agents,
including bioreductive radiosensitizers and alkylating drugs
such as melphalan.
We have compared the efficacy of hydralazine and other
established vasoactive agents including 5-hydroxytryptamine
(5-HT), nifedipine and verapamil for their ability to increase
the anti-tumour effectiveness of melphalan. Treating mice
with hydralazine 15min after melphalan results in an
enhancement of , 3.0 for melphalan induced delay in growth
of either the RIF-I or KHT tumours. Similar enhancements
are achieved when hydralizine is given before melphalan.
Administration of 5-HT also enhances tumour response but
only when given after melphalan. Both hydralazine and 5-
HT can induce close to 100% radiobiological hypoxia in the
RIF-l and KHT tumours. In contrast, nifedipine has no
effect on tumour hypoxia fraction at a dose (10mgkg-1)
which nonetheless substantially increases the anti-tumour
effectiveness of melphalan. Hydralazine can also produce up
to a 10-fold increase in the sensitizing efficiency of misoni-
dazole and RSU 1069 in the KHT tumour in mice. This is
likely to be due to the vasoactive agent inducing close to
100% tumour hypoxia after irradiation and so allowing
greater expression of the differential toxicity of the sensi-
tizers towards those hypoxic cells surviving the radiation
treatment. Other radiosensitizers have been combined with
hydralazine and it was found that the sensitizing efficiency of
etanidazole and Ro 07-9963 was not significantly improved
by subsequent administration of hydralazine. There was a
small (2-4 fold) improvement in the sensitizing efficiency of
pimonidazole. Only with RSU 1069 and misonidazole were
substantial increases observed.
These results will be discussed in terms of the bioreduc-
tive cytotoxic effects of each of these compounds following
treatment with hydralazine. Further, comparison will be
made with the action of left-shifters of the oxyhaemoglobin
association curve for their ability to induce severe tumour
hypoxia.
Molecular enzymology of bioreductive metabolism
P. Workman, M.I. Walton & K.L. Kooistra
MRC Clinical Oncology and Radiotherapeutics Unit, MRC
Centre, Cambridge, UK.
Bioreductive activation of hypoxic cell-targetted cytotoxins is
accelerated by the catalytic functions of a variety of
enzymes. These are fairly well characterized for rodent liver
and include microsomal enzymes cytochrome P-450 reduc-
tase and cytosolic xanthine oxidase and aldehyde oxidase.
Much less is known about the enzymology of bioreductive
activation in tumours.
We have investigated the bioreduction of the hypoxic
sensitizers/cytotoxins benznidazole (2-nitroimidazole),
CB 1954 (dinitrophenyl aziridine), SR 4233 (benzotriazene di-
N-oxide) and E09 (aziridinyl indoloquinone). Tools used
include specific inhibitors and substrates, inhibitory anti-
bodies and purified enzymes. All reactions are inhibited or
reversed by molecular oxygen, except reduction of CB 1954
by DT-diaphorase which predominates in the rat Walker
tumour. Substrate and cofactor requirements differ. Involve-
ment of each enzyme depends upon the drug and the
particular stage of the multistep reduction sequence. For
example, in mouse liver microsomes, P-450 reductase is
predominantly involved in early events of benznidazole
reduction while for SR4233 the former enzyme has only a
limited capability for direct reduction. For CB 1954,
metabolism at the 4-nitro position predominates over the 2-
position. Characterization of cytochrome P-450 isoenzyme
specificities is underway.
We propose that rational selection of hypoxic cell cyto-
toxins could be based upon enzymological characterization
of the reductases present in a biopsy specimen. This will be
facilitated by development of (1) conventional and flow
cytometric assays for specific reductases, and (2) techniques
for non-invasive identification of hypoxic cells in vivo.
Progress in these areas will be described.
Vasoactive agents - Clinical potential?
N.P. Rowell
MRC Radiobiology Unit, Harwell and Radiotherapy Unit,
The Royal Marsden Hospital, Sutton, Surrey, UK.
The potential for vasodilators to enhance bioreductive cyto-
toxicity in man depends not only on the development of
bioreductives of low toxicity, but also on the ability of
vasodilators to produce the necessary reduction in tumour
blood flow without serious cardiovascular sequelae.
The physiol'ogical changes necessary to produce a fall in
tumour blood flow are discussed with reference to a simple
mathematical model incorporating the normal physiological
responses to vasodilator therapy.
A study investigating the effects of single-dose hydralazine
on tumour blood flow is discussed.